Rapid Identification and Classification of Vibrio parahaemolyticus

JP2023547535A5Pending Publication Date: 2024-11-11BECTON DICKINSON & CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527011
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-05
Filing Date
2021-11-04
Publication Date
2024-11-11

AI Technical Summary

Technical Problem

Current methods for detecting Vibrio parahaemolyticus, a leading cause of gastroenteritis, are cumbersome, time-consuming, and lack specificity, and existing PCR methods struggle to accurately identify both the bacterium and its virulence factors simultaneously, leading to potential false negatives due to PCR inhibitors or reagent failures.

Method used

A multiplex real-time PCR method using primer pairs and oligonucleotide probes specifically designed to hybridize with the toxR, trh, and tdh genes of Vibrio parahaemolyticus, along with an E. coli internal control (yaiO gene), enabling simultaneous detection and identification of the bacterium and its virulence factors in a single reaction.

Benefits of technology

The method provides rapid, sensitive, and specific detection of Vibrio parahaemolyticus and its virulence factors, reducing false negatives by incorporating internal controls and allowing for accurate identification of both virulent and non-virulent strains.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed herein are methods and compositions for detecting V. parahaemolyticus, V. parahaemolyticus encoding TDH-related hemolysin (TRH), and V. parahaemolyticus encoding thermostable direct hemolysin (TDH). In some embodiments, the presence or absence of V. parahaemolyticus, V. parahaemolyticus encoding TDH-related hemolysin (TRH), and / or V. parahaemolyticus encoding thermostable direct hemolysin (TDH) in a sample is determined using a multiplex nucleic acid-based test.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims the benefit of PCT Application No. PCT / CN2020 / 126679, filed November 5, 2020, the contents of which are incorporated herein by reference in their entirety and for all purposes.

[0002] Sequence Listing This application is filed with a Sequence Listing in electronic format. The Sequence Listing is presented as a 12 kb file entitled 68EB-298747-WO2.TXT, created on October 29, 2021. The information in the electronic format for the Sequence Listing is incorporated herein by reference in its entirety.

[0003] The present disclosure relates to methods and compositions for detecting and classifying V. parahaemolyticus in a sample. More particularly, the present disclosure relates to the detection of V. parahaemolyticus, including V. parahaemolyticus encoding TRH-related hemolysin (TRH) and V. parahaemolyticus encoding thermostable direct hemolysin (TDH), in a sample, such as a fecal sample, using nucleic acid-based testing. [Background technology]

[0004] Vibrio parahaemolyticus is a Gram-negative halophilic bacterium that is the leading causative agent of acute gastroenteritis in humans. Infections caused by V. parahaemolyticus can be fatal in patients with liver dysfunction or immunocompromise. Since 2006, three major V. parahaemolyticus outbreaks have been recorded across 13 states in the United States, resulting in approximately 284 reported cases. Recent studies indicate that V. parahaemolyticus has developed multiple antimicrobial resistance, which could pose a significant public health problem. Thermostable direct hemolysin (tdh) and TDH-related hemolysin (trh) are two major virulence factors associated with V. parahaemolyticus that are closely related to its pathogenicity. Epidemiological studies have indicated that tdh is one of the major virulence factors in V. parahaemolyticus and is frequently found in almost all (95%) clinical isolates. Furthermore, tdh / trh is the only gene accepted as a virulence marker by ISO (ISO, 2007) and the FDA. Risk assessment for V. parahaemolyticus is an increasingly important issue in countries with high seafood intake levels, including Korea, Japan, Taiwan, and China. Therefore, highly specific, sensitive, and rapid detection of this bacterium is important for public health. Timely identification of patients infected with V. parahaemolyticus and identification of virulence factors are important for patient treatment and disease control. Therefore, there is a need to develop a more efficient and rapid method for detecting V. parahaemolyticus, such as a multiplex real-time PCR method that simultaneously detects four gene targets, and that can detect V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin), all in a single reaction.There is a need for multiplexed compositions and methods for identifying V. parahaemolyticus and simultaneously determining its virulence potential. Summary of the Invention

[0005] In some embodiments, a method for detecting V. parahaemolyticus in a sample is provided. In some embodiments, the method includes contacting the sample with a plurality of primer pairs, the plurality of primer pairs including at least one primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 1-8 or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 1-8; at least one primer pair capable of hybridizing to the trh (TDH-related hemolysin) gene of V. parahaemolyticus, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 14-23 or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 14-23; and a tdh (thermostable direct hemolysin) gene of V. parahaemolyticus. The method may include a step of including at least one primer pair capable of hybridizing to a V. parahaemolysin (TRH) gene, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 29-38, or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 29-38. The method may include a step of generating an amplicon of a toxR gene sequence, an amplicon of a trh gene sequence, an amplicon of a tdh gene sequence, or any combination thereof, when the sample contains one or more of V. parahaemolysin, V. parahaemolysin encoding TRH (TDH-related hemolysin), and V. parahaemolysin encoding TDH (thermostable direct hemolysin).The method may include determining the presence or amount of one or more amplicons as an indication of the presence of one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin) in the sample. The method may include contacting the sample with at least one control primer pair capable of hybridizing to the yaiO gene of Escherichia coli (E. coli), wherein each primer in the at least one control primer pair comprises any one of the sequences set forth in SEQ ID NOs: 44-53 or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 44-53; and, if the sample contains E. coli, generating an amplicon of the E. coli yaiO gene sequence from the sample; and determining the presence or amount of the amplicon of the E. coli yaiO gene sequence in the sample as an indication of the presence of E. coli.

[0006] In some embodiments, the sample is contacted with a composition comprising a plurality of primer pairs and at least one control primer pair capable of hybridizing to the yaiO gene of E. coli. In some embodiments, the sample is a biological sample or an environmental sample. In some embodiments, the environmental sample is obtained from a food sample, a beverage sample, a paper surface, a fabric surface, a metal surface, a wood surface, a plastic surface, a soil sample, a freshwater sample, a wastewater sample, a saltwater sample, exposure to air or other gas samples, cultures thereof, or any combination thereof. In some embodiments, the biological sample is obtained from a tissue sample, saliva, blood, plasma, serum, feces, urine, sputum, mucus, lymph, synovial fluid, cerebrospinal fluid, ascites, pleural effusion, seroma, pus, a skin swab or mucosal surface, cultures thereof, or any combination thereof. In some embodiments, the biological sample comprises or is derived from a fecal sample.

[0007] In some embodiments, the plurality of primer pairs comprises a first primer comprising the sequence of SEQ ID NO: 1, 3, 5, or 7, a second primer comprising the sequence of SEQ ID NO: 2, 4, 6, or 8, a third primer comprising the sequence of SEQ ID NO: 14, 16, 18, 20, or 22, a fourth primer comprising the sequence of SEQ ID NO: 15, 17, 19, 21, or 23, a fifth primer comprising the sequence of SEQ ID NO: 29, 31, 33, 35, or 37, and a sixth primer comprising the sequence of SEQ ID NO: 30, 32, 34, 36, or 38. In some embodiments, the plurality of primer pairs comprises a seventh primer comprising the sequence of SEQ ID NO: 44, 46, 48, 50, or 52, and an eighth primer comprising the sequence of SEQ ID NO: 45, 47, 49, 51, or 53. In some embodiments, the primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus is SEQ ID NO: 1 and 2, SEQ ID NO: 3 and 4, SEQ ID NO: 5 and 6, or SEQ ID NO: 7 and 8; the primer pair capable of hybridizing to the trh gene of V. parahaemolyticus is SEQ ID NO: 14 and 15, SEQ ID NO: 16 and 17, SEQ ID NO: 18 and 19, SEQ ID NO: 20 and 21, or SEQ ID NO: 22 and 23; and the primer pair capable of hybridizing to the tdh gene of V. parahaemolyticus is SEQ ID NO: 29 and 30, SEQ ID NO: 31 and 32, SEQ ID NO: 33 and 34, SEQ ID NO: 35 and 36, or SEQ ID NO: 37 and 38. In some embodiments, the control primer pair capable of hybridizing to the yaiO gene of E. coli is SEQ ID NO: 44 and 45, SEQ ID NO: 46 and 47, SEQ ID NO: 48 and 49, SEQ ID NO: 50 and 51, or SEQ ID NO: 52 and 53.

[0008] In some embodiments, the amplification is carried out using a method selected from the group consisting of polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), replicase-mediated amplification, immunoamplification, nucleic acid sequence-based amplification (NASBA), self-sustained sequence replication (3SR), rolling circle amplification, and transcription-mediated amplification (TMA). In some embodiments, the PCR is real-time PCR. In some embodiments, the PCR is quantitative real-time PCR (QRT-PCR). In some embodiments, each primer comprises an exogenous nucleotide sequence.

[0009] In some embodiments, determining the presence or amount of one or more amplicons comprises contacting the amplicon with a plurality of oligonucleotide probes, wherein each of the plurality of oligonucleotide probes comprises a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, 54-58, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, 54-58. In some embodiments, each of the plurality of oligonucleotide probes comprises a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, 54-58. In some embodiments, each of the plurality of oligonucleotide probes consists of a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, 54-58. In some embodiments, each probe is flanked by a complementary sequence at the 5' end and a complementary sequence at the 3' end. In some embodiments, one of the complementary sequences comprises a fluorescent-emitting moiety and the other complementary sequence comprises a fluorescent-quenching moiety, hi some embodiments, at least one of the plurality of oligonucleotide probes comprises a fluorescent-emitting moiety and a fluorescent-quenching moiety.

[0010] In some embodiments, a composition for detecting V. parahaemolyticus is provided. In some embodiments, the composition includes at least one primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 1-8 or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 1-8; at least one primer pair capable of hybridizing to the trh (TDH-related hemolysin) gene of V. parahaemolyticus, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 14-23 or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 14-23; and a tdh (thermostable direct hemolysin) gene of V. parahaemolyticus. The composition includes at least one primer pair capable of hybridizing to the yaiO gene of Escherichia coli, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 29 to 38, or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 29 to 38. The composition may include at least one control primer pair capable of hybridizing to the yaiO gene of Escherichia coli, wherein each primer in the at least one control primer pair comprises any one of the sequences set forth in SEQ ID NOs: 44 to 53, or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 44 to 53.

[0011] In some embodiments, at least one primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus comprises a primer comprising the sequence of SEQ ID NO: 1, 3, 5, or 7 and a primer comprising the sequence of SEQ ID NO: 2, 4, 6, or 8; at least one primer pair capable of hybridizing to the trh gene of V. parahaemolyticus comprises a primer comprising the sequence of SEQ ID NO: 14, 16, 18, 20, or 22 and a primer comprising the sequence of SEQ ID NO: 15, 17, 19, 21, or 23; and at least one primer pair capable of hybridizing to the tdh gene of V. parahaemolyticus comprises a primer comprising the sequence of SEQ ID NO: 29, 31, 33, 35, or 37 and a primer comprising the sequence of SEQ ID NO: 30, 32, 34, 36, or 38. In some embodiments, at least one control primer pair capable of hybridizing to the yaiO gene of E. coli comprises a primer comprising the sequence of SEQ ID NO: 44, 46, 48, 50, or 52, and a primer comprising the sequence of SEQ ID NO: 45, 47, 49, 51, or 53.

[0012] The composition may comprise a plurality of oligonucleotide probes, wherein each of the plurality of oligonucleotide probes comprises a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58. In some embodiments, each of the plurality of oligonucleotide probes comprises a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58. In some embodiments, each of the plurality of oligonucleotide probes consists of a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58. In some embodiments, at least one of the plurality of probes comprises a fluorescent moiety and a fluorescent quenching moiety. Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the toxR gene of V. parahaemolyticus. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 1-13, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-13. In some embodiments, the probe or primer consists of a sequence selected from the group consisting of SEQ ID NOs: 1-13, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-13. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 1-13. In some embodiments, the probe or primer consists of a sequence selected from the group consisting of SEQ ID NOs: 1-13.

[0013] Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the trh (TDH-related hemolysin) gene of V. parahaemolyticus. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 14-28, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 14-28. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 14-28, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 14-28. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 14-28. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 14-28.

[0014] Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the tdh (thermostable direct hemolysin) gene of V. parahaemolyticus. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 29-43, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 29-43. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 29-43, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 29-43. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 29-43. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 29-43.

[0015] Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the yaiO gene of Escherichia coli. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 44-58, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 44-58. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 44-58, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 44-58. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 44-58. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 44-58.

[0016] Disclosed herein are compositions. In some embodiments, the compositions comprise one or more of the oligonucleotide probes and primers disclosed herein, or two or more of the oligonucleotide probes and primers. In some embodiments, the compositions further comprise one or more of the enzymes for extending and / or amplifying nucleic acids. DETAILED DESCRIPTION OF THE INVENTION

[0017] In the following detailed description, reference is made to the accompanying drawings, which form a part of this specification. In the drawings, like symbols typically identify like elements, unless context dictates otherwise. The exemplary embodiments described in the detailed description, drawings, and claims are not intended to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein and illustrated in the drawings, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are expressly contemplated herein and form a part of the present disclosure herein. With respect to related art, all patents, published patent applications, other publications, and sequences from GenBank and other databases mentioned herein are incorporated by reference in their entirety.

[0018] Identification of V. parahaemolyticus is routinely performed by performing biochemical tests upon isolation of the organism from selective agar plates. However, phenotypic identification of V. parahaemolyticus has certain drawbacks, such as being too tedious, time-consuming, and not very effective in terms of detection specificity. PCR has been used for the rapid identification of this species and the detection of its virulence genes (Bej et al., 1999; Kim et al., 1999; Bauer & Rorvik, 2007). The major virulence genes, tdh and trh, have been used as diagnostic markers to identify pathogenic isolates of V. parahaemolyticus by PCR (Bilung et al., 2005; Marlina et al., 2007; Nordstrom et al., 2007). However, because these virulence genes are absent in some strains, including some nonpathogenic strains, PCR assays based on these virulence genes do not accurately identify all V. parahaemolyticus strains. Because these nonpathogenic strains may be carriers of virulence genes, specific molecular markers are needed to accurately identify V. parahaemolyticus by PCR. Specific markers, such as the toxR gene encoding a transcriptional regulator, have been used to unambiguously identify V. parahaemolyticus by PCR (Bej et al., 1999), but they do not provide information about potential pathogenicity. Tada et al. (2000) detected V. parahaemolyticus by PCR targeted to the tdh (thermostable direct hemolysin) and trh (tdh-related hemolysin) genes. However, these currently available methods cannot simultaneously identify V. parahaemolyticus strains and detect virulence genes. Amy V. Rizvi et al. (2010) reported a SYBR Green I-based multiplex real-time PCR method for detecting pathogenic V. parahaemolyticus.Although cost-effective, this method is not as sensitive and specific as TaqMan probe-based real-time PCR. Anjay et al. (2016) developed a method targeting the genes tdh, trh, and toxR for the detection of pathogenic and pandemic V. parahaemolyticus in fish and crustacean isolates, but did not incorporate an internal control. The absence of an internal control can lead to false-negative results, primarily caused by PCR inhibitors, instrument failure, or reagent malfunction. In some embodiments, a TaqMan probe-based multiplex real-time PCR assay for the specific detection of virulent and non-virulent V. parahaemolyticus strains is provided, which uses both species-specific and toxin genes in a single reaction and can incorporate an internal control to prevent false-negative results and indicate the quality of the fecal sample.

[0019] Provided herein are methods and compositions for detecting one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding thermostable direct hemolysin (TDH) in a sample. Primers and probes can bind to specific genes for V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding thermostable direct hemolysin (TDH) in a sample, such as a biological sample. In some embodiments, multiplex nucleic acid amplification can be performed to enable detection of one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding thermostable direct hemolysin (TDH) in the sample in a single assay.

[0020] In some embodiments, a method for detecting V. parahaemolyticus in a sample is provided. In some embodiments, the method includes contacting the sample with a plurality of primer pairs, the plurality of primer pairs including at least one primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 1-8 or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 1-8; at least one primer pair capable of hybridizing to the trh (TDH-related hemolysin) gene of V. parahaemolyticus, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 14-23 or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 14-23; and a tdh (thermostable direct hemolysin) gene of V. parahaemolyticus. The method may include a step of including at least one primer pair capable of hybridizing to a V. parahaemolysin (TRH) gene, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 29-38, or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 29-38. The method may include a step of generating an amplicon of a toxR gene sequence, an amplicon of a trh gene sequence, an amplicon of a tdh gene sequence, or any combination thereof, when the sample contains one or more of V. parahaemolysin, V. parahaemolysin encoding TRH (TDH-related hemolysin), and V. parahaemolysin encoding TDH (thermostable direct hemolysin).The method may include determining the presence or amount of one or more amplicons as an indication of the presence of one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin) in the sample. The method may include contacting the sample with at least one control primer pair capable of hybridizing to the yaiO gene of E. coli, wherein each primer in the at least one control primer pair comprises any one of the sequences set forth in SEQ ID NOs: 44-53 or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 44-53; and, if the sample contains E. coli, generating an amplicon of the E. coli yaiO gene sequence from the sample; and determining the presence or amount of the amplicon of the E. coli yaiO gene sequence in the sample as an indication of the presence of E. coli.

[0021] In some embodiments, a composition for detecting V. parahaemolyticus is provided. In some embodiments, the composition includes at least one primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 1-8 or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 1-8; at least one primer pair capable of hybridizing to the trh (TDH-related hemolysin) gene of V. parahaemolyticus, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 14-23 or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 14-23; and a tdh (thermostable direct hemolysin) gene of V. parahaemolyticus. The composition includes at least one primer pair capable of hybridizing to the yaiO gene of Escherichia coli, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 29 to 38, or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 29 to 38. The composition may include at least one control primer pair capable of hybridizing to the yaiO gene of Escherichia coli, wherein each primer in the at least one control primer pair comprises any one of the sequences set forth in SEQ ID NOs: 44 to 53, or a sequence exhibiting at least about 85% identity to any one of the sequences set forth in SEQ ID NOs: 44 to 53.

[0022] The composition may comprise a plurality of oligonucleotide probes, wherein each of the plurality of oligonucleotide probes comprises a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58. In some embodiments, each of the plurality of oligonucleotide probes comprises a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58. In some embodiments, each of the plurality of oligonucleotide probes consists of a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58. In some embodiments, at least one of the plurality of probes comprises a fluorescent moiety and a fluorescent quenching moiety. Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the toxR gene of V. parahaemolyticus. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 1-13, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-13.

[0023] Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the trh (TDH-related hemolysin) gene of V. parahaemolyticus. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 14-28, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 14-28. Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the tdh (thermostable direct hemolysin) gene of V. parahaemolyticus. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 29-43, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 29-43.

[0024] Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the yaiO gene of E. coli. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 44-58, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 44-58. Also disclosed herein are compositions, e.g., compositions that include one or more of the oligonucleotide probes and primers disclosed herein, or two or more of the oligonucleotide probes and primers, and optionally include one or more enzymes for extending and / or amplifying nucleic acids.

[0025] definition As used herein, the term "nucleic acid" may refer to a polynucleotide sequence, or a fragment thereof. A nucleic acid may comprise nucleotides. A nucleic acid may be exogenous or endogenous to a cell. A nucleic acid may be present in a cell-free environment. A nucleic acid may be a gene or a fragment thereof. A nucleic acid may be DNA. A nucleic acid may be RNA. A nucleic acid may comprise one or more analogs (e.g., modified backbones, sugars, or nucleobases). Some non-limiting examples of analogs include 5-bromouracil, peptide nucleic acids, xenonucleic acids, morpholinos, locked nucleic acids, glycol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, fluorophores (e.g., rhodamine or fluorescein linked to the sugar), thiol-containing nucleotides, biotin-linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudouridine, dihydrouridine, queosine, and wiosine. "Nucleic acid," "polynucleotide," "target polynucleotide," "target nucleic acid," and "target sequence" may be used interchangeably. As used herein, "nucleic acid" may refer to a polymeric compound containing nucleosides or nucleoside analogs having nitrogenous heterocyclic bases or base analogs linked together by nucleic acid backbone linkages (e.g., phosphodiester ester bonds) to form a polynucleotide. Non-limiting examples of nucleic acids include RNA, DNA, and analogs thereof. The nucleic acid backbone can include one or more of a variety of linkages, such as sugar-phosphodiester ester linkages, peptide-nucleic acid linkages, phosphorothioate linkages, or methylphosphonate linkages, or mixtures of such linkages within a single oligonucleotide. The sugar moiety in a nucleic acid can be ribose, deoxyribose, or similar compounds with known substitutions. The term nucleic acid includes conventional nitrogenous bases (e.g., A, G, C, T, U), known base analogs (e.g., inosine), derivatives of purine or pyrimidine bases, and "abasic" residues (i.e., no nitrogenous base is found at one or more backbone positions).That is, nucleic acids may contain only conventional sugars, bases, and linkages found in RNA and DNA, or may contain both conventional components and substitutions (e.g., conventional bases and analogs linked via a methoxy backbone, or conventional bases and one or more base analogs linked via an RNA or DNA backbone).

[0026] Nucleic acids can contain one or more modifications (e.g., base modifications, backbone modifications) to confer new or enhanced features (e.g., improved stability) to the nucleic acid. Nucleic acids can contain nucleic acid affinity tags. A nucleoside can be a base-sugar combination. The base portion of a nucleoside can be a heterocyclic base. The two most common classes of such heterocyclic bases are purines and pyrimidines. A nucleotide can be a nucleoside that further includes a phosphate group covalently linked to the sugar portion of the nucleoside. In nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2', 3', or 5' hydroxyl moiety of the sugar. In forming nucleic acids, the phosphate group can covalently link adjacent nucleosides to each other to form a linear polymeric compound. The respective ends of this linear polymeric compound can then be further connected to form a circular compound, although linear compounds are generally suitable. In addition, linear compounds can have internal nucleotide base complementarity and therefore can fold to form fully double-stranded or partially double-stranded compounds. Within nucleic acids, the phosphate groups are generally sometimes referred to as forming the internucleoside backbone of the nucleic acid. The linkage or backbone can be a 3'-5' phosphodiester linkage.

[0027] The nucleic acid may contain modified backbones and / or modified internucleoside linkages, including those that have a phosphorus atom or that do not have a phosphorus atom in the backbone. Suitable modified nucleic acid backbones containing a phosphorus atom therein can include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methylphosphonates, and other alkyl phosphonates such as 3'-alkylene phosphonates, 5'-alkylene phosphonates, and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkyl phosphoramidates, phosphorodiamidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs thereof, and analogs with reverse polarity where one or more internucleotide linkages are 3'-3', 5'-5', or 2'-2' linkages.

[0028] Nucleic acids can contain polynucleotide backbones formed with short alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or internucleoside linkages with one or more short chain heteroatoms or heterocycles. These polynucleotide backbones include polynucleotide backbones with morpholino linkages (formed in part from the sugar portion of the nucleoside), siloxane backbones, sulfide, sulfoxide, and sulfone backbones, formacetyl and thioformacetyl backbones, methyleneformacetyl and thioformacetyl backbones, riboacetyl backbones, alkene-containing backbones, sulfamate backbones, methyleneimino and methylenehydrazino backbones, sulfonate and sulfonamide backbones, amide backbones, and other polynucleotide backbones with mixed N-, O-, S-, and CH2 moieties.

[0029] Nucleic acids may include nucleic acid mimetics. The term "mimetics" may be intended to include polynucleotides in which only the furanose ring or both the furanose ring and the internucleotide linkage are replaced with groups other than furanose; replacement of only the furanose ring may also be referred to as a sugar surrogate. The heterocyclic base moiety or modified heterocyclic base moiety may be maintained for hybridization with an appropriate target nucleic acid. One such nucleic acid may be a peptide nucleic acid (PNA). Within a PNA, the sugar backbone of a polynucleotide may be replaced with an amide-containing backbone, particularly an aminoethylglycine backbone. The nucleotides may be retained and may be directly or indirectly linked to the aza nitrogen atoms of the amide portion of the backbone. The backbone within a PNA compound may contain two or more linked aminoethylglycine units, resulting in an amide-containing backbone for PNAs. The heterocyclic base moiety may be directly or indirectly linked to the aza nitrogen atoms of the amide portion of the backbone. The nucleic acid may include a morpholino backbone structure. For example, the nucleic acid may include a six-membered morpholino ring instead of a ribose ring. In some of these embodiments, phosphorodiamidate or other non-phosphodiester internucleoside linkages may replace the phosphodiester linkages.

[0030] Nucleic acids can include linked morpholino units (e.g., morpholino nucleic acids) having heterocyclic bases joined to a morpholino ring. Linking groups can link morpholino monomer units within a morpholino nucleic acid. Morpholino-based nonionic oligomeric compounds can reduce undesired interactions with intracellular proteins. Morpholino-based polynucleotides can be nonionic mimics of nucleic acids. Various compounds within the morpholino class can be connected using different linking groups. A further class of polynucleotide mimics can be referred to as cyclohexenyl nucleic acids (CeNA). The furanose ring normally present in nucleic acid molecules can be replaced with a cyclohexenyl ring. CeNA DMT-protected phosphoramidite monomers can be prepared and used to synthesize oligomeric compounds using phosphoramidite chemistry. Incorporation of CeNA monomers into nucleic acid chains can increase the stability of DNA / RNA hybrids. The oligoadenylates of CeNA can form complexes with nucleic acid complements with stability similar to that of natural complexes. Further modifications can include locked nucleic acids (LNAs), in which a 2'-hydroxyl group is linked to the 4' carbon atom of the sugar ring, thereby forming a 2'-C,4'-C-oxymethylene linkage, thereby forming a bicyclic sugar moiety. The linkage can be a methylene (-CH2) group bridging the 2' oxygen atom and the 4' carbon atom, where n is 1 or 2. LNAs and LNA analogs exhibit extremely high duplex thermal stability (T) with complementary nucleic acids. m = +3 to +10°C), stability against degradation by 3'-exonucleases, and good solubility properties.

[0031] Nucleic acids can also include modifications or substitutions of nucleobases (often simply referred to as "bases"). As used herein, "unmodified" or "natural" nucleobases can include purine bases (e.g., adenine (A), guanine (G)), pyrimidine bases (e.g., thymine (T), cytosine (C), and uracil (U)). Modified nucleobases include 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine, and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C=C-CH3)uracil and cytosine, and other alkynyl derivatives of pyrimidine bases, 6-azouracil, cytosine, and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-haloadenine and guanine, 8-aminoadenine and 8-aminoguanine. Other synthetic and natural nucleobases may be included, such as uracil, 8-thiol and guanine, 8-thioalkyl and guanine, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halouracil and cytosine, particularly 5-bromouracil and cytosine, 5-trifluoromethyluracil and other 5-substituted cytosines, 7-methylguanine and adenine, 2-F-adenine, 2-aminoadenine, 8-azaguanine and adenine, 7-deazaguanine and adenine, and 3-deazaguanine and adenine.Modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido(5,4-b)(1,4)benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido(5,4-b)(1,4)benzothiazin-2(3H)-one), substituted phenoxazine cytidines (e.g., 9-(2-aminoethoxy)-H-pyrimido(5,4-(b)(1,4)benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido(5,4-b)(1,4)benzothiazin-2(3H)-one), G-clamps may include G-clamps such as 9-(2-aminoethoxy)-H-pyrimido(5,4-(b)(1,4)benzoxazin-2(3H)-one), substituted phenoxazine cytidines (e.g., 9-(2-aminoethoxy)-H-pyrimido(5,4-(b)(1,4)benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido(4,5-b)indol-2-one), and pyridoindole cytidine (H-pyrido(3',2':4,5)pyrrolo[2,3-d]pyrimidin-2-one).

[0032] As used herein, the term "isolating nucleic acids" may refer to the purification of nucleic acids from one or more subcellular components. Those skilled in the art will understand that a sample processed to "isolate nucleic acids" may contain components and contaminants other than nucleic acids. A sample containing isolated nucleic acids may be prepared from a specimen using any acceptable method known in the art. For example, cells may be lysed using known lysing agents, and nucleic acids may be purified or partially purified from other subcellular components. Suitable reagents and protocols for DNA and RNA extraction may be found, for example, in U.S. Patent Application Publication Nos. US2010-0009351 and US2009-0131650, each of which is incorporated herein by reference in its entirety. For nucleic acid tests (e.g., amplification and hybridization methods discussed in more detail below), the extracted nucleic acid solution can be added directly to the reagents (e.g., in liquid, matrix-bound, lyophilized form, etc., as discussed in more detail below) required to perform the test according to embodiments disclosed herein.

[0033] As used herein, a "template" may refer to all or a portion of a polynucleotide that contains at least one target nucleotide sequence. As used herein, the term "primer" may refer to a polynucleotide that can be used to initiate a nucleic acid chain extension reaction. The length of a primer can vary, for example, from about 5 to about 100 nucleotides, about 10 to about 50 nucleotides, about 15 to about 40 nucleotides, or about 20 to about 30 nucleotides. The length of a primer can be about 10 nucleotides, about 20 nucleotides, about 25 nucleotides, about 30 nucleotides, about 35 nucleotides, about 40 nucleotides, about 50 nucleotides, about 75 nucleotides, about 100 nucleotides, or a range between any two of these values. In some embodiments, primers have a length of 10 to about 50 nucleotides, i.e., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more nucleotides. In some embodiments, primers have a length of 18 to 32 nucleotides.

[0034] As used herein, "probe" may refer to a polynucleotide capable of hybridizing (e.g., specifically) to a target sequence within a nucleic acid under conditions that allow hybridization, thereby permitting detection of the target sequence or amplified nucleic acid. The "target" of a probe generally refers to a sequence within an amplified nucleic acid sequence, or a subset thereof, that specifically hybridizes to at least a portion of a probe oligomer through standard hydrogen bonding (i.e., base pairing). A probe may contain a target-specific sequence and other sequences that contribute to the three-dimensional conformation of the probe. Sequences are "sufficiently complementary" if they allow stable hybridization of a probe oligomer to a target sequence that is not completely complementary to the target-specific sequence of the probe under appropriate hybridization conditions. The length of a probe may vary, for example, from about 5 to about 100 nucleotides, from about 10 to about 50 nucleotides, from about 15 to about 40 nucleotides, or from about 20 to about 30 nucleotides. The length of the probe can be about 10 nucleotides, about 20 nucleotides, about 25 nucleotides, about 30 nucleotides, about 35 nucleotides, about 40 nucleotides, about 50 nucleotides, about 100 nucleotides, or a range between any two of these values. In some embodiments, the probe has a length of 10 to about 50 nucleotides. For example, the primers and / or probes can be at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 nucleotides, or more in length. In some embodiments, the probe can be non-sequence specific.

[0035] Preferably, primers and / or probes can be between 8 and 45 nucleotides in length. For example, primers and / or probes can be at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, or more nucleotides in length. Primers and probes can be modified to contain additional nucleotides at the 5' or 3' end, or both. Those skilled in the art will understand that additional bases to the 3' end of an amplification primer (but not necessarily a probe) will generally be complementary to the template sequence. Primer and probe sequences can also be modified to remove nucleotides at the 5' or 3' end. Those skilled in the art will understand that to function for amplification, a primer or probe will be of the minimum length and annealing temperature disclosed herein.

[0036] Primers and probes were prepared by melting temperature (T m ) are capable of binding to their targets at an annealing temperature, which is a temperature below T m " and "melting temperature" are interchangeable terms that refer to the temperature at which 50% of a population of double-stranded polynucleotide molecules dissociates into single strands. m The formula for calculating T is well known. m is expressed by the following formula: m = 69.3 + 0.41 × (G+C)% / L, where L is the length of the probe in nucleotides. m may also be estimated using the formula adapted from hybridization assays in 1M salt: [(number of A+T) x 2°C + (number of G+C) x 4°C], and generally refers to the T of the PCR primer. mcan be used to calculate T. See, for example, CR Newton et al. PCR, 2nd ed., Springer-Verlag (New York: 1997), p. 24 (hereby incorporated by reference in its entirety). m Other more sophisticated calculations exist that take into account structural as well as sequence features for the calculation of the melting temperature of an oligonucleotide. The melting temperature of an oligonucleotide can depend on the complementarity of the oligonucleotide primer or probe to the binding sequence and the salt conditions. In some embodiments, the oligonucleotide primers or probes provided herein can be purified in a 50 mM KCl, 10 mM Tris-HCl buffer at a T of less than about 90° C., for example, about 89° C., 88, 87, 86, 85, 84, 83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39° C. or less, including ranges between any two of the recited values. m It has. In some embodiments, the primers disclosed herein, e.g., amplification primers, can be provided as an amplification primer pair, e.g., comprising a forward primer and a reverse primer (a first amplification primer and a second amplification primer). Preferably, the forward primer and the reverse primer differ by T that do not differ by more than 10°C, e.g., by less than 10°C, less than 9°C, less than 8°C, less than 7°C, less than 6°C, less than 5°C, less than 4°C, less than 3°C, less than 2°C, or less than 1°C. m It has.

[0037] Primer and probe sequences can be modified by having nucleotide substitutions (compared to the target sequence) within the oligonucleotide sequence, provided that the oligonucleotide contains sufficient complementarity to specifically hybridize to the target nucleic acid sequence. In this manner, at least 1, 2, 3, 4, or up to about 5 nucleotides can be substituted. As used herein, the term "complementarity" can refer to sequence complementarity between regions of two polynucleotide strands or between two regions of the same polynucleotide strand. When the two regions are arranged antiparallel, a first region of a polynucleotide is complementary to a second region of the same or a different polynucleotide, and at least one nucleotide of the first region can base pair with a base of the second region. Therefore, base pairing between two complementary polynucleotides is not required at every nucleotide position. "Fully complementary" can refer to a first polynucleotide that is 100% complementary or "fully" complementary to a second polynucleotide, thus forming base pairs at every nucleotide position. "Partially complementary" can also refer to a first polynucleotide that is not 100% complementary (e.g., 90%, 80%, or 70% complementary) but contains mismatched nucleotides at one or more nucleotide positions. In some embodiments, the oligonucleotide comprises a universal base.

[0038] As used herein, "exogenous nucleotide sequence" may refer to a sequence introduced by a primer or probe used for amplification such that the amplification product contains the exogenous nucleotide sequence and the target nucleotide sequence in an arrangement not found in the original template from which the target nucleotide sequence was copied. As used herein, when applied to nucleic acid molecules, "sequence identity" or "percent identical" can refer to the percentage of nucleic acid residues in a candidate nucleic acid molecule sequence that are identical to the subject nucleic acid molecule sequence, after aligning the sequences to achieve the maximum percent identity and not considering any nucleic acid residue substitutions as part of the sequence identity. Nucleic acid sequence identity can be determined using any method known in the art, e.g., CLUSTALW, T-COFFEE, BLASTN.

[0039] As used herein, "sufficiently complementary" may refer to a contiguous nucleic acid base sequence that is capable of hybridizing to another base sequence through hydrogen bonding between the series of complementary bases. A complementary base sequence may be complementary at every position within the oligomer sequence using standard base pairing (e.g., G:C, A:T, or A:U pairing), or may contain one or more residues that are not complementary (including non-basic positions), such that the entire complementary base sequence is capable of specifically hybridizing to another base sequence under appropriate hybridization conditions. The contiguous bases can be at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100% complementary to the sequence to which the oligomer is intended to hybridize. A substantially complementary sequence can refer to a sequence having a percent identity of 100, 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80, 75, 70, or less, or any range of values ​​therebetween, compared to a reference sequence. Those skilled in the art can readily select appropriate hybridization conditions, which may be predicted based on the composition of the base sequence or may be determined using routine tests. (See, e.g., Green and Sambrook, Molecular Cloning, A Laboratory Manual, 4th ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2012)). As used herein, the term "multiplex PCR" refers to a type of PCR in which more than one primer set is included in a reaction that allows a single target, or two or more different targets, to be amplified in a single reaction vessel (e.g., test tube). Multiplex PCR can be, for example, real-time PCR.

[0040] Oligonucleotides and compositions containing them As described herein, nucleic acid amplification can be performed to determine the presence, absence, type, and / or level of one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding thermostable direct hemolysin (TDH) in a sample. In some embodiments, the presence, absence, and / or level of one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding thermostable direct hemolysin (TDH) is determined by detecting one or more target genes of each of the target organisms using methods known in the art, such as DNA amplification. In some embodiments, multiplex PCR may be performed to detect the presence, absence, or levels of one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin).

[0041] In some embodiments, primer and probe combinations for multiplex real-time PCR (polymerase chain reaction) are provided, as well as detection methods for simultaneously identifying and determining the virulence potential of V. parahaemolyticus. In some embodiments, methods (e.g., multiplex RT PCR assays) and compositions (e.g., primers and probes) are provided that target the species-specific toxR gene, trh encoding TRH (TDH-related hemolysin), and tdh encoding TDH (thermostable direct hemolysin), which are present in all strains of V. parahaemolyticus and used as markers for the species. Additionally, some embodiments of the methods and compositions presented herein utilize the Escherichia coli-specific yaiO gene as an internal control marker added to multiplex PCR to indicate false-negative results (e.g., caused by PCR inhibitors, instrument or reagent malfunctions).

[0042] Disclosed herein are methods and compositions (e.g., reagents utilizing fluorescent sequence-specific hybridization probes) that provide a rapid and inexpensive solution for (1) identifying V. parahaemolyticus strains; (2) detecting thermostable direct hemolysin (TDH) and TDH-related hemolysin (TRH); (3) monitoring the quality of fecal samples; and / or (4) quality control of DNA extraction and real-time PCR processes. The methods presented herein may include subjecting DNA from a sample (e.g., a fecal sample) or culture suspected of containing V. parahaemolyticus to multiplex polymerase chain reaction amplification using four sets of concentration-optimized primer pairs and probes; treating the reaction mixture under optimal thermal conditions; and detecting amplification of the DNA target by monitoring the fluorescent signal of hydrolysis (TaqMan®) probes during each cycle and interpreting the data and reporting the final results at the end of the program. Disclosed herein are multiplex PCR primers and probes that were designed and screened using primer design software Primer 3 and Beacon Designer. Four sets of optimized primers and probes may include the primers and probes shown in Table 1. The compositions and methods presented herein achieve rapid and sensitive detection and differentiation of critically important diarrheal pathogens.

[0043] In some embodiments, compositions and methods for TaqMan probe-based real-time multiplex PCR are provided. Disclosed herein are compositions (e.g., reagents) and methods (e.g., assays) for TaqMan probe-based multiplex real-time PCR for rapid identification and classification of Vibrio parahaemolyticus. Compared to currently available methods, advantages of the present invention include: (1) the ability to simultaneously detect four gene targets using an established multiplex PCR method, in which V. parahaemolyticus identification, TDH (thermostable direct hemolysin), and TRH (TDH-related hemolysin) detection can be achieved in a single PCR reaction; (2) the ability to monitor the quality of stool samples using a designed internal control, which can primarily indicate false-negative results caused by PCR inhibitors, instrument failure, or reagent malfunction; and (3) the primer / probe combinations and multiplex real-time PCR methods disclosed herein can achieve high sensitivity, inclusiveness, and specificity. Furthermore, the disclosed methods are quick and easy to perform.

[0044] Each of the targets, V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin), can be detected using a separate channel in DNA amplification. In some embodiments, it may be desirable to use a single fluorescent channel to detect the presence, absence, and / or levels of two or more V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin). In some embodiments, such a combination may reduce the amount of reagents required to perform an experiment and provide an accurate qualitative standard by which a determination about V. parahaemolyticus can be assessed.

[0045] Oligonucleotides (e.g., amplification primers and probes) are provided that are capable of specifically hybridizing (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions and / or stringent hybridization conditions) to target gene regions, or their complements, in V. parahaemolyticus, in V. parahaemolyticus encoding TRH (TDH-related hemolysin), and in V. parahaemolyticus encoding TDH (thermostable direct hemolysin). In some embodiments, amplification of a target gene region of an organism in a sample (e.g., a fecal sample) can indicate the presence, absence, and / or level of the organism in the sample.

[0046] The target gene region can vary. In some embodiments, the species-specific toxR gene, present in all strains of V. parahaemolyticus, is used as a marker for the species. In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that are capable of specifically hybridizing (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions and / or stringent hybridization conditions) to the gene region encoding toxR in V. parahaemolyticus. In some embodiments, the toxR gene is used as a target gene for DNA amplification to detect the presence, absence, and / or level of V. parahaemolyticus in a sample. In some embodiments, primers and probes capable of specifically binding to the toxR gene region of V. parahaemolyticus are used in detecting the presence, absence, and / or level of V. parahaemolyticus in a biological sample. Examples of oligonucleotides capable of specifically hybridizing to the toxR gene region in V. parahaemolyticus include, but are not limited to, sequences exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-13, and SEQ ID NOs: 1-13, as presented in Table 1.

[0047] In some embodiments, trh is used as a marker for V. parahaemolyticus that encodes TRH (TDH-related hemolysin). In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that are capable of specifically hybridizing (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions and / or stringent hybridization conditions) to a region of the gene encoding trh in V. parahaemolyticus. In some embodiments, the trh gene is used as a target gene for DNA amplification to detect the presence, absence, and / or level of V. parahaemolyticus that encodes TRH (TDH-related hemolysin) in a sample. In some embodiments, primers and probes that can specifically bind to a region of the trh gene of V. parahaemolyticus are used in detecting the presence, absence, and / or level of V. parahaemolyticus that encodes trh in a biological sample. Examples of oligonucleotides capable of specifically hybridizing to the trhN gene region in V. parahaemolyticus include, but are not limited to, sequences exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 14-28 and SEQ ID NOs: 14-28 presented in Table 1.

[0048] In some embodiments, tdh is used as a marker for V. parahaemolyticus that encodes thermostable direct hemolysin (TDH). In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that are capable of specifically hybridizing (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions and / or stringent hybridization conditions) to a region of the gene encoding tdh in V. parahaemolyticus. In some embodiments, the tdh gene is used as a target gene for DNA amplification to detect the presence, absence, and / or level of V. parahaemolyticus that encodes thermostable direct hemolysin (TDH) in a sample. In some embodiments, primers and probes that can specifically bind to a region of the tdh gene of V. parahaemolyticus are used in detecting the presence, absence, and / or level of V. parahaemolyticus that encodes tdh in a biological sample. Examples of oligonucleotides capable of specifically hybridizing to the tdh gene region in V. parahaemolyticus include, but are not limited to, sequences exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 29-43 and SEQ ID NOs: 29-43 presented in Table 1.

[0049] Additionally, in some embodiments of the methods and compositions provided herein, the E. coli -specific yaiO gene is utilized as an internal control marker added to multiplex PCR to indicate false-negative results (e.g., caused by PCR inhibitors, instrument or reagent malfunctions). In some embodiments, oligonucleotides (e.g., amplification primers and probes) are provided that are capable of specifically hybridizing (e.g., under standard nucleic acid amplification conditions, e.g., under standard PCR conditions and / or stringent hybridization conditions) to a gene region encoding yaiO in E. coli. In some embodiments, the yaiO gene is used as a target gene for DNA amplification to detect the presence, absence, and / or level of E. coli in a sample. In some embodiments, primers and probes capable of specifically binding to the E. coli yaiO gene region are used in detecting the presence, absence, and / or level of E. coli in a biological sample (e.g., as an internal control). Examples of oligonucleotides capable of specifically hybridizing to the yaiO gene region in E. coli include, but are not limited to, sequences exhibiting at least about 85% identity to SEQ ID NOs: 44-58 and sequences selected from the group consisting of SEQ ID NOs: 44-58 presented in Table 1.

[0050] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4]

[0051] Also provided herein are oligonucleotides (e.g., amplification primers or probes) containing one, two, three, four, or more mismatched or universal nucleotides compared to SEQ ID NOs: 1-58 or their complements, including oligonucleotides that are at least 80% identical (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to SEQ ID NOs: 1-58 or their complements. In some embodiments, the oligonucleotide comprises a sequence selected from SEQ ID NOs: 1-58. In some embodiments, the oligonucleotide comprises a sequence that is at least about 85% identical to a sequence selected from SEQ ID NOs: 1-58. In some embodiments, the oligonucleotide consists of a sequence selected from SEQ ID NOs: 1-58. In some embodiments, the oligonucleotide consists of a sequence that is at least about 85% identical, or at least about 95% identical, to a sequence selected from SEQ ID NOs: 1-58. In some embodiments, the final reaction concentration of the primers provided herein is about 300 nM. In some embodiments, the final reaction concentration of the probes provided herein is about 100 nM.

[0052] In some embodiments, a primer / probe combination is provided. The primer / probe combination may include a forward primer, a reverse primer, and a probe (e.g., A3-toxR-FP, A3-toxR-RP, and A3-toxR-probe in tandem). The compositions and methods provided herein may include one or more of the primer / probe combinations provided in Table 1. For example, a method or composition may include an A3 primer / probe combination (e.g., A3-toxR-FP, A3-toxR-RP, and A3-toxR-probe in tandem). Disclosed herein are methods and compositions that include two or more primer / probe combinations (e.g., multiplexed reactions). For example, a method or composition can include a primer / probe combination of A3, B3, C3, and D3 (e.g., A3-toxR-FP, A3-toxR-RP, A3-toxR-probe, B3-trh-FP, B3-trh-RP, B3-trh-probe, C3-tdh-15F, C3-tdh-15R, C3-tdh-probe, D3-yaiO-FP, D3-yaiO-RP, and D3-yaiO-probe in tandem).As used herein, the term "primer / probe combinations" refers to: (1) one or more primer / probe combinations (e.g., A1, A2, A3, and / or A4) capable of specifically hybridizing to the sequence of the toxR gene of V. parahaemolyticus or its complement; (2) one or more primer / probe combinations (e.g., B1, B2, B3, and / or B4) capable of specifically hybridizing to the sequence of the trh gene of V. parahaemolyticus encoding TRH (TDH-related hemolysin) or its complement; (3) one or more primer / probe combinations (e.g., B1, B2, B3, and / or B4) capable of specifically hybridizing to the sequence of the trh gene of V. parahaemolyticus encoding TRH (thermostable direct hemolysin); (3) one or more primer / probe combinations (e.g., C1, C2, C3, C4, and / or C5) capable of specifically hybridizing to the sequence of the tdh gene of V. parahaemolyticus, encoding tdh (hemolysin), or its complement; and / or (4) one or more primer / probe combinations (e.g., D1, D2, D3, D4, and / or D5) capable of specifically hybridizing to the sequence of the yaiO gene of E. coli, or its complement. Disclosed herein are methods and compositions comprising one or more of the primer / probe combinations presented in Table 2. Disclosed herein are methods and compositions comprising one or more of the primer / probe combinations presented in Table 3.

[0053] [Table 2-1] [Table 2-2]

[0054] [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5]

[0055] The nucleic acids provided herein may be in a variety of forms. For example, in some embodiments, the nucleic acids are dissolved in a solution, such as a buffer (alone or in combination with other various nucleic acids). In some embodiments, the nucleic acids are provided as a salt, alone or in combination with other isolated nucleic acids. In some embodiments, the nucleic acids are provided in a lyophilized form that can be reconstituted. For example, in some embodiments, the isolated nucleic acids disclosed herein may be provided in a lyophilized pellet alone or in a lyophilized pellet with other isolated nucleic acids. In some embodiments, the nucleic acids are provided immobilized on a solid material, such as a bead, membrane, or the like. In some embodiments, the nucleic acids are provided within a host cell, for example, within a cell line harboring a plasmid or a cell line harboring a stably integrated sequence.

[0056] In some embodiments, compositions, reaction mixtures, and kits comprise one or more amplification primer pairs capable of specifically hybridizing to a sequence of the toxR gene of V. parahaemolyticus or its complement. In some embodiments, compositions, reaction mixtures, and kits comprise one or more probes capable of specifically hybridizing to a sequence of the toxR gene of V. parahaemolyticus or its complement. Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the toxR gene of V. parahaemolyticus. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 1-13, or a sequence 1 exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-13. In some embodiments, the probe or primer consists of a sequence selected from the group consisting of SEQ ID NOs: 1-13, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-13. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 1-13. In some embodiments, the probe or primer consists of a sequence selected from the group consisting of SEQ ID NOs: 1-13.

[0057] In some embodiments, compositions, reaction mixtures, and kits comprise one or more amplification primer pairs capable of specifically hybridizing to a sequence of the trh (TDH-related hemolysin) gene of V. parahaemolyticus or its complement. In some embodiments, compositions, reaction mixtures, and kits comprise one or more probes capable of specifically hybridizing to a sequence of the trh gene of V. parahaemolyticus or its complement. Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the trh gene of V. parahaemolyticus. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 14-28, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 14-28. In some embodiments, the probe or primer consists of a sequence selected from the group consisting of SEQ ID NOs: 14-28, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 14-28. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 14-28. In some embodiments, the probe or primer consists of a sequence selected from the group consisting of SEQ ID NOs: 14-28.

[0058] In some embodiments, compositions, reaction mixtures, and kits comprise one or more amplification primer pairs capable of specifically hybridizing to a sequence of the V. parahaemolyticus thermostable direct hemolysin (tdh) gene or its complement. In some embodiments, compositions, reaction mixtures, and kits comprise one or more probes capable of specifically hybridizing to a sequence of the V. parahaemolyticus tdh gene or its complement. Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the V. parahaemolyticus tdh gene. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 29-43, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 29-43. In some embodiments, the probe or primer consists of a sequence selected from the group consisting of SEQ ID NOs: 29-43, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 29-43. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 29-43. In some embodiments, the probe or primer consists of a sequence selected from the group consisting of SEQ ID NOs: 29-43.

[0059] In some embodiments, the compositions, reaction mixtures, and kits comprise one or more amplification primer pairs capable of specifically hybridizing to a sequence of the yaiO gene of E. coli or its complement. In some embodiments, the compositions, reaction mixtures, and kits comprise one or more probes capable of specifically hybridizing to a sequence of the yaiO gene of E. coli or its complement. Disclosed herein are probes or primers of about 100 nucleotides or less in length that are capable of hybridizing to the yaiO gene of E. coli. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 44-58, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 44-58. In some embodiments, the probe or primer consists of a sequence selected from the group consisting of SEQ ID NOs: 44-58, or a sequence exhibiting at least about 85% identity, at least about 90% identity, or at least about 95% identity to a sequence selected from the group consisting of SEQ ID NOs: 44-58. In some embodiments, the probe or primer comprises a sequence selected from the group consisting of SEQ ID NOs: 44-58. In some embodiments, the probe or primer consists of a sequence selected from the group consisting of SEQ ID NOs: 44-58. In some embodiments, compositions are provided that include one or more of the oligonucleotide probes and / or primers, or two or more of the oligonucleotide probes and / or primers disclosed herein.

[0060] In some embodiments, the oligonucleotide probes may comprise a detection moiety. For example, the oligonucleotide probes disclosed herein may comprise a radioactive label. Non-limiting examples of radioactive labels include: 3 H, 14 C. 32 P, and 35In some embodiments, the oligonucleotide probe may include one or more non-radioactive detection markers or moieties, including, but not limited to, ligands, fluorophores, chemiluminescent agents, enzymes, and antibodies. Other detection markers for use with the probes, which may enable increased sensitivity of the methods of the present invention, include biotin and radioactive nucleotides. It will be apparent to those skilled in the art that the choice of a particular label will determine the manner in which it is attached to the probe. For example, the oligonucleotide probe is labeled with one or more dyes such that a detectable change in fluorescence occurs upon hybridization with the template nucleic acid. For some applications, non-specific dyes may be desirable, but sequence-specific probes may provide more accurate measurements of amplification. One configuration of a sequence-specific probe may include one end of the probe tethered to a fluorophore and the other end of the probe tethered to a quencher. When unhybridized, the probe may maintain a stem-loop configuration in which the fluorophore is quenched by the quencher, thereby preventing the fluorophore from fluorescing. When hybridized to a template nucleic acid sequence, the probe is linearized, distancing the fluorophore from the quencher and allowing the fluorophore to fluoresce. Another configuration of the sequence-specific probe may include a first probe tethered to a first fluorophore of a FRET pair and a second probe tethered to a second fluorophore of the FRET pair. When hybridized to the same amplicon, the first and second probes may be configured to hybridize to sequences of the amplicon within sufficient proximity to allow energy transfer by FRET.

[0061] In some embodiments, the probe is a TaqMan probe. The TaqMan probe may comprise a fluorophore and a quencher. The quencher molecule may quench the fluorescence emitted by the fluorophore upon excitation by the cycler's light source via Förster resonance energy transfer (FRET). As long as the fluorophore and quencher are in close proximity, quenching may inhibit any detectable (e.g., fluorescent) signal. The TaqMan probes provided herein may be designed to anneal within the DNA region amplified by the primers provided herein. Without being bound by any particular theory, in some embodiments, as a PCR polymerase (e.g., Taq) extends the primer and synthesizes a nascent strand on a single-stranded template, the 5'-3' exonuclease activity of the PCR polymerase degrades the probe annealed to the template. Degradation of the probe releases the fluorophore from the probe and cleaves it in proximity to the quencher, thereby eliminating the quenching effect and allowing the fluorophore to fluoresce. Thus, in some embodiments, the fluorescence detected in a quantitative PCR thermal cycler can be directly proportional to the amount of fluorophore released and the amount of DNA template present in the PCR.

[0062] In some embodiments, the sequence-specific probe comprises an oligonucleotide disclosed herein conjugated to a fluorophore. In some embodiments, the probe is conjugated to two or more fluorophores. Examples of fluorophores include xanthene dyes, such as fluorescein isothiocyanate (FITC), 2-[ethylamino)-3-(ethylimino)-2-7-dimethyl-3H-xanthen-9-yl]benzoic acid ethyl ester monohydrochloride (R6G) (emitting response radiation in the wavelength range of about 500-560 nm), 1,1,3,3,3',3'-hexamethylindodicarbocyanine iodide (HIDC) (emitting response radiation in the wavelength range of about 600-660 nm), 6-carboxyfluorescein (commonly known by the abbreviations FAM and F), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HDC), and 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HDC). fluorescein dyes and rhodamine dyes such as 4',5'-dichloro-2',7'-dimethoxyfluorescein (HEX), 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE or J), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA or T), 6-carboxy-X-rhodamine (ROX or R), 5-carboxyrhodamine-6G (R6G5 or G5), 6-carboxyrhodamine-6G (R6G6 or G6), and rhodamine 110; cyanine dyes, such as Cy3 dyes, Cy5 dyes, and Cy7 dyes; coumarins, such as umbelliferone; benzimide dyes, such as Hoechst 33258; phenanthridine dyes, such as Texas Red; ethidium dyes; acridine dyes; carbazole dyes; phenoxazine dyes; porphyrin dyes; polymethine dyes, such as cyanine dyes such as Cy3 (emitting response radiation in the wavelength range of about 540 to 580 nm) and Cy5 (emitting response radiation in the wavelength range of about 640 to 680 nm); BODIPY dyes and quinoline dyes.Specific fluorophores of interest include pyrene, coumarin, diethylaminocoumarin, FAM, chlorotriazinylfluorescein, fluorescein, R110, eosin, JOE, R6G, HIDC, tetramethylrhodamine, TAMRA, Lissamine, ROX, naphthofluorescein, Texas Red, naphthofluorescein, Cy3 and Cy5, CAL fluor orange, and the like. Other examples of fluorescein dyes include 6-carboxyfluorescein (6-FAM), 2',4',1,4-tetrachlorofluorescein (TET), 2',4',5',7',1,4-hexachlorofluorescein (HEX), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyrhodamine (JOE), 2'-chloro-5'-fluoro-7',8'-fused phenyl-1,4-dichloro-6-carboxyfluorescein (NED), and 2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfluorescein (VIC). The probe may comprise SpC6 or its functional equivalents and derivatives. The probe may comprise a spacer moiety. The spacer moiety may comprise an alkyl group having at least 2 carbons to about 12 carbons. The probe may comprise a spacer comprising an abasic unit. The probe may comprise a spacer selected from the group consisting of idSp, iSp9, iS18, iSpC3, iSpC6, iSpC12, or any combination thereof.

[0063] In some embodiments, the probe is conjugated to a quencher. Quenchers absorb electromagnetic radiation and dissipate it as heat, thereby maintaining a dark color. Exemplary quenchers include Dabcyl, NFQ such as BHQ-1 or BHQ-2 (Biosearch), IOWA BLACK FQ (IDT), and IOWA BLACK RQ (IDT). In some embodiments, the quencher is selected to pair with the fluorophore so as to absorb electromagnetic radiation emitted by the fluorophore. Fluorophore / quencher pairs useful in the compositions and methods disclosed herein are well known in the art and may be found, for example, in Marras, "Selection of Fluorophore and Quencher Pairs for Fluorescent Nucleic Acid Hybridization Probes," available at www.molecular-beacons.org / download / marras,mmb06%28335%293.pdf. Examples of quenching moieties include, but are not limited to, dark quenchers, Black Hole Quencher® (BHQ®) (e.g., BHQ-0, BHQ-1, BHQ-2, BHQ-3), Qx1 quenchers, ATTO quenchers (e.g., ATTO 540Q, ATTO 580Q, and ATTO 612Q), dimethylaminoazobenzenesulfonic acid (Dabsyl), Iowa Black RQ, Iowa Black FQ, IRDye QC-1, QSY dyes (e.g., QSY 7, QSY 9, QSY 21), AbsoluteQuencher, Eclipse, and metal clusters such as gold nanoparticles. Examples of ATTO quenchers include, but are not limited to, ATTO 540Q, ATTO 580Q, and ATTO 612Q. Examples of Black Hole Quencher® (BHQ®) include, but are not limited to, BHQ-0 (493 nm), BHQ-1 (534 nm), BHQ-2 (579 nm), and BHQ-3 (672 nm).

[0064] In some embodiments, the detection label is an Alexa Fluor® dye (e.g., Alexa Fluor® 350, Alexa Fluor® 405, Alexa Fluor® 430, Alexa Fluor® 488, Alexa Fluor® 500, Alexa Fluor® 514, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 555, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 610, Alexa Fluor® 633, Alexa Fluor® 635, Alexa Fluor® 647, Alexa Fluor® 660, Alexa Fluor® 680, Alexa Fluor® 700, Alexa Fluor® 750, Alexa Fluor® 790), an ATTO dye (e.g., ATTO 390, ATTO 425, ATTO 490), or a ATTO dye (e.g., ATTO 500, ATTO 514, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 555, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 610, Alexa Fluor® 633, Alexa Fluor® 635, Alexa Fluor® 647, Alexa Fluor® 660, Alexa Fluor® 680, Alexa Fluor® 700, Alexa Fluor® 750, Alexa Fluor® 790). 465, ATTO 488, ATTO 495, ATTO 514, ATTO 520, ATTO 532, ATTO Rho6G, ATTO 542, ATTO 550, ATTO 565, ATTO Rho3B, ATTO Rho11, ATTO Rho12, ATTO Thio12, ATTO 590, ATTO 594, ATTO Rhol3, ATTO 610, ATTO 620, ATTO Rhol4, ATTO 633, ATTO 647, ATTO 647N, ATTO 655, ATTO Oxal2, ATTO 665, ATTO 680, ATTO 700, ATTO 725, ATTO740), DyFight dyes, cyanine dyes (e.g., Cy2, Cy3, Cy3.5, Cy3b, Cy5, Cy5.5, Cy7, Cy7.5) The fluorescent label is selected from FluoProbes dyes, Sulfo Cy dyes, Seta dyes, IRIS dyes, SeTau dyes, SRfluor dyes, Square dyes, fluorescein isothiocyanate (FITC), tetramethylrhodamine (TRITC), Texas Red, Oregon Green, Pacific Blue, Pacific Green, Pacific Orange, quantum dots, and tethered fluorescent proteins.

[0065] In some embodiments, a fluorophore is conjugated to a first end of the probe and a quencher is conjugated to a second end of the probe. In some embodiments, a probe may comprise two or more fluorophores. In some embodiments, a probe may comprise two or more quencher moieties. In some embodiments, a probe may comprise one or more quencher moieties and / or one or more fluorophores. A quencher moiety or fluorophore may be conjugated to any portion of the probe (e.g., on the 5' end, on the 3' end, or in the middle of the probe). Any probe nucleotide may comprise a fluorophore or quencher moiety, such as BHQ1dT. The conjugation may comprise a covalent bond and may include at least one linker molecule disposed between the probe and the fluorophore or quencher. In some embodiments, a fluorophore is conjugated to the 5' end of the probe and a quencher is conjugated to the 3' end of the probe. In some embodiments, the fluorophore is attached to the 3' end of the probe, and the quencher is attached to the 5' end of the probe. Examples of probes that can be used in quantitative nucleic acid amplification include molecular beacons, SCORPION™ probes (Sigma), TAQMAN™ probes (Life Technologies), etc. Other nucleic acid detection technologies useful in the embodiments disclosed herein include, but are not limited to, nanoparticle probe technology (see Elghanian, et al. (1997) Science 277:1078-1081) and Amplifluor probe technology (see U.S. Patent Nos. 5,866,366; 6,090,592; 6,117,635; and 6,117,986).

[0066] In some embodiments, compositions for detecting V. parahaemolyticus are provided, including at least one primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus, wherein each primer in the at least one primer pair comprises a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences set forth in SEQ ID NOs: 1-8; at least one primer pair capable of hybridizing to the V. parahaemolysin (tdh) gene, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 14 to 23, or a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences set forth in SEQ ID NOs: 14 to 23; and The present invention also includes at least one primer pair capable of hybridizing to the hemolysin gene, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 29 to 38, or a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences set forth in SEQ ID NOs: 29 to 38.The composition may include at least one control primer pair capable of hybridizing to the yaiO gene of E. coli, wherein each primer in the at least one control primer pair comprises any one of the sequences set forth in SEQ ID NOs: 44-53, or a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences set forth in SEQ ID NOs: 44-53.

[0067] In some embodiments, at least one primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus comprises a primer comprising the sequence of SEQ ID NO: 1, 3, 5, or 7 and a primer comprising the sequence of SEQ ID NO: 2, 4, 6, or 8; at least one primer pair capable of hybridizing to the trh gene of V. parahaemolyticus comprises a primer comprising the sequence of SEQ ID NO: 14, 16, 18, 20, or 22 and a primer comprising the sequence of SEQ ID NO: 15, 17, 19, 21, or 23; and at least one primer pair capable of hybridizing to the tdh gene of V. parahaemolyticus comprises a primer comprising the sequence of SEQ ID NO: 29, 31, 33, 35, or 37 and a primer comprising the sequence of SEQ ID NO: 30, 32, 34, 36, or 38. In some embodiments, at least one control primer pair capable of hybridizing to the yaiO gene of E. coli comprises a primer comprising the sequence of SEQ ID NO: 44, 46, 48, 50, or 52, and a primer comprising the sequence of SEQ ID NO: 45, 47, 49, 51, or 53.

[0068] The composition may comprise a plurality of oligonucleotide probes, wherein each of the plurality of oligonucleotide probes comprises a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58, or a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58. Each of the plurality of oligonucleotide probes may comprise a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58. Each of the multiple types of oligonucleotide probes can consist of a sequence selected from the group consisting of SEQ ID NOs: 9 to 13, 24 to 28, 39 to 43, and 54 to 58. At least one of the multiple types of probes can include a fluorescent moiety and a fluorescent quenching moiety. Any of the probes described herein can include a fluorescence-emitting moiety, a fluorescence-quenching moiety, or both.

[0069] As disclosed herein, the reaction mixture may include one or more of the primers disclosed herein, one or more of the probes disclosed herein (e.g., fluorophore-containing probes), or any combination thereof. In some embodiments, the reaction mixture includes one or more of the primer- and / or probe-containing compositions disclosed herein. The reaction mixture may also include a variety of additional components. Examples of additional components in the reaction mixture include, but are not limited to, template DNA, a DNA polymerase (e.g., Taq DNA polymerase), deoxynucleotides (dNTPs), a buffer, divalent cations, monovalent cations, potassium ions, and any combination thereof. In some embodiments, the reaction mixture is a master mix for real-time PCR.

[0070] sample Disclosed herein are methods and compositions suitable for detecting one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin) in a wide variety of samples. As used herein, "sample" may refer to any type of biological material collected from a subject suspected of having V. parahaemolyticus, in one or more instances. Samples may include, for example, bodily fluids, tissues, or cells. Samples may include biological material collected directly from a subject, cultured cells or tissues, or any fraction or product made from or derived from biological material. Samples may be purified, partially purified, unpurified, enriched, or amplified.

[0071] The sample may be a biological sample, e.g., a clinical sample. In some embodiments, the sample is collected from a biological source, such as the vagina, urethra, penis, anus, throat, cervix, fermentation broth, or cell culture. The sample may include, for example, cells derived from bodily fluids and fecal samples. Biological samples may be (i) used directly as obtained from a subject or source, or (ii) used after pretreatment to alter the characteristics of the sample. Thus, a test sample may be pretreated before use, for example, by disrupting cells or viral particles, preparing a liquid from solid materials, diluting mucus, filtering the liquid, concentrating the liquid, inactivating interfering components, adding reagents, purifying nucleic acids, etc. Thus, as used herein, "biological sample" includes nucleic acids (DNA, RNA, or total nucleic acids) extracted from a clinical or biological specimen. Sample preparation may also include using solutions containing buffers, salts, detergents, etc., used to prepare the sample for analysis. In some embodiments, the sample is processed before molecular testing. In some embodiments, the sample is analyzed directly and is not pretreated before testing. The sample can be, for example, a fecal sample. In some embodiments, the sample is a fecal sample from a patient with clinical symptoms of acute gastroenteritis. Fecal samples are often infected with multiple organisms, and the disclosed primers and probes are tolerant to mixed infections of fecal samples.

[0072] In some embodiments, the test sample is processed before performing the methods disclosed herein. For example, in some embodiments, the sample may be isolated, concentrated, or subjected to various other processing steps before performing the methods disclosed herein. For example, in some embodiments, the sample may be processed to isolate nucleic acids from the sample before contacting the sample with an oligonucleotide disclosed herein. In some embodiments, the methods disclosed herein are performed on the sample without culturing the sample in vitro. In some embodiments, the methods disclosed herein are performed on the sample without isolating nucleic acids from the sample before contacting the sample with an oligonucleotide disclosed herein.

[0073] A sample can contain one or more nucleic acids (e.g., multiple nucleic acids). As used herein, the term "multiple" can refer to two or more species. Thus, in some embodiments, a sample contains two or more (e.g., three or more, five or more, ten or more, twenty or more, fifty or more, one hundred or more, five hundred or more, one thousand or more, or five thousand or more) nucleic acids (e.g., gDNA, mRNA). The disclosed methods can be used as an extremely sensitive format for detecting a target nucleic acid (e.g., the toxR gene of V. parahaemolyticus) present in a sample (e.g., in a complex mixture of nucleic acids, such as gDNA). In some embodiments, a sample contains 5 or more nucleic acids (e.g., 10 or more, 20 or more, 50 or more, 100 or more, 500 or more, 1,000 or more, or 5,000 or more nucleic acids) that differ from each other in sequence. 3 Seed or more, 5 x 10 3 species or more, 10 4 Seed or more, 5 x 10 4 species or more, 10 5 Seed or more, 5 x 10 5 species or more, 10 6 Seed or more, 5 x 10 6 species or more, or 10 7 It includes nucleic acids of a species or more.

[0074] In some embodiments, the sample may be 10-20 species, 20-50 species, 50-100 species, 100-500 species, 500-103 seeds, 10 3 ~5×10 3 Seeds, 5x10 3 ~10 4 seeds, 10 4 ~5×10 4 Seeds, 5x10 4 ~10 5 seeds, 10 5 ~5×10 5 Seeds, 5x10 5 ~10 6 seeds, 10 6 ~5×10 6 Seeds or 5 x 10 6 ~10 7 seeds or 10 7 In some embodiments, the sample contains more than 5-10 species of nucleic acid. 7 Nucleic acids of different species (e.g., different in sequence from each other) (e.g., 5-10 6 , 5 to 10 5 , 5-50,000, 5-30,000, 10-10 6 , 10~10 5 , 10-50,000, 10-30,000, 20-10 6 , 20~10 5 , 20-50,000, or 20-30,000 nucleic acids, or a number or range of numbers between any two of these values). In some embodiments, the sample contains 20 or more nucleic acids that differ in sequence from each other.

[0075] As used herein, the term "sample" can refer to any sample containing nucleic acids (e.g., for determining whether a target sequence is present in a population of nucleic acids). A sample can be derived from any source; for example, a sample can be a synthetic combination of purified nucleic acids; a sample can be a cell lysate, a DNA-enriched cell lysate, or nucleic acids isolated and / or purified from a cell lysate. A sample can be derived from a patient (e.g., for diagnostic purposes). A sample can be derived from permeabilized cells. A sample can be derived from crosslinked cells. A sample can be cells within a tissue section. A sample can be derived from tissue prepared by crosslinking followed by delipidation and correction to provide a uniform refractive index.

[0076] A "sample" can include a target nucleic acid (e.g., the toxR gene of V. parahaemolyticus) and multiple non-target nucleic acids. In some embodiments, the target nucleic acid is present in a sample at 1 copy per 10 non-target nucleic acids, 1 copy per 20 non-target nucleic acids, 1 copy per 25 non-target nucleic acids, 1 copy per 50 non-target nucleic acids, 1 copy per 100 non-target nucleic acids, 1 copy per 500 non-target nucleic acids, 1 copy per 10 3 1 copy per species non-target nucleic acid, 5 x 10 3 1 copy per species non-target nucleic acid, 10 4 1 copy per species non-target nucleic acid, 5 x 10 4 1 copy per species non-target nucleic acid, 10 5 1 copy per species non-target nucleic acid, 5 x 10 5 1 copy per species non-target nucleic acid, 10 6 1 copy per species non-target nucleic acid, 10 6 In some embodiments, the target nucleic acid is present in the sample at a copy number of less than 1 copy per species of non-target nucleic acid, or at a number or range between any two of these values. In some embodiments, the target nucleic acid is present in the sample at a copy number of between 1 copy per 10 species of non-target nucleic acid and 1 copy per 20 species of non-target nucleic acid, between 1 copy per 20 species of non-target nucleic acid and 1 copy per 50 species of non-target nucleic acid, between 1 copy per 50 species of non-target nucleic acid and 1 copy per 100 species of non-target nucleic acid, between 1 copy per 100 species of non-target nucleic acid and 1 copy per 500 species of non-target nucleic acid, between 1 copy per 500 species of non-target nucleic acid and 10 3 1 copy per species non-target nucleic acid, 10 3 1 copy per species of non-target nucleic acid ~5 x 10 3 1 copy per species non-target nucleic acid, 5 x 10 3 1 copy per species of non-target nucleic acid ~10 4 1 copy per species non-target nucleic acid, 10 4 1 copy per species of non-target nucleic acid ~10 5 1 copy per species non-target nucleic acid, 10 5 1 copy per species of non-target nucleic acid ~10 61 copy per species of non-target nucleic acid, or 10 6 1 copy per species of non-target nucleic acid ~10 7 It is present at 1 copy per non-target nucleic acid of the species, or at a number or range of copies between any two of these values.

[0077] Suitable samples include, but are not limited to, saliva samples, blood samples, serum samples, plasma samples, urine samples, aspirate samples, and biopsy samples. Thus, with respect to a patient, the term "sample" encompasses blood and other biologically derived liquid samples, solid tissue samples such as biopsy specimens or tissue cultures, or cells derived therefrom and their progeny. The definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents; washing; or enrichment for certain cell populations, such as cancer cells. The definition also includes samples enriched for specific types of molecules, e.g., nucleic acids. The term "sample" encompasses biological samples, such as clinical samples, such as blood, plasma, serum, aspirate, cerebrospinal fluid (CSF), and also includes tissue obtained by surgical resection, tissue obtained by biopsy, cells in culture, cell supernatants, cell lysates, tissue samples, organs, bone marrow, and the like. "Biological sample" includes bodily fluids derived therefrom (e.g., cancerous cells, infected cells, etc.), e.g., samples containing nucleic acids obtained from such cells (e.g., cell lysates or other cell extracts containing nucleic acids).

[0078] Suitable samples for use in the methods disclosed herein include any conventional biological sample obtained from an organism or part thereof, such as a plant, animal, or bacterium. In certain embodiments, the biological sample is obtained from an animal subject, such as a human subject. A biological sample is any solid or fluid sample obtained from, excreted, or secreted by any organism, including, but not limited to, unicellular organisms such as bacteria, yeast, protozoa, and amoebas, multicellular organisms (such as plants or animals, including samples from apparently healthy human subjects or human patients who are healthy or suffering from a condition or disease to be diagnosed or detected, such as infection with a pathogenic microorganism, such as a pathogenic bacterium or virus), among others. For example, the biological sample can be a bodily fluid obtained from, e.g., blood, plasma, serum, urine, feces, sputum, mucus, lymphatic fluid, synovial fluid, bile, ascites, pleural effusion, seroma, saliva, cerebrospinal fluid, aqueous humor, or vitreous humor, or any secretion, exudate, transudate (e.g., bodily fluid obtained from an abscess or any other site of infection or inflammation), or a bodily fluid obtained from a joint (e.g., a normal joint or a joint affected by a disease such as rheumatoid arthritis, osteoarthritis, gout, or septic arthritis), or a skin swab or mucosal surface.

[0079] A sample may also be a sample obtained from any organ or tissue (including a biopsy specimen, such as a tumor biopsy, or an autopsy specimen), and may include cells (whether primary or cultured cells) or medium conditioned by any cell, tissue, or organ. Exemplary samples include, but are not limited to, cells, cell lysates, blood smears, cytocentrifuge preparations, cytology smears, bodily fluids (e.g., blood, plasma, serum, saliva, sputum, urine, bronchoalveolar lavage fluid, semen, etc.), tissue biopsies (e.g., tumor biopsies), fine needle aspirates, and / or tissue sections (e.g., cryostat tissue sections and / or paraffin-embedded tissue sections). In other examples, the sample includes circulating tumor cells (which may be identified by cell surface markers). In certain instances, samples may be used directly (e.g., freshly collected or frozen samples) or may be manipulated prior to use, for example, by fixation (e.g., using formalin) and / or embedding in wax (such as formalin-fixed, paraffin-embedded (FFPE) tissue samples). Any method of obtaining tissue from a subject may be utilized, and it will be understood that the choice of method used will depend on a variety of factors, such as the type of tissue, the age of the subject, or the procedures available to the testing personnel. Standard techniques for collecting such samples are available in the art. In other embodiments, the sample may be an environmental sample such as water, soil, or a surface such as an industrial or medical surface. Due to the increased sensitivity provided by the embodiments disclosed herein, in certain exemplary embodiments, the assays and methods may be performed on crude samples, where the target molecules to be detected are not further fractionated or purified from the sample.

[0080] Sample extraction In a typical sample extraction, cells are lysed by mechanical shearing with glass beads to lyse the target organism, as described in U.S. Patent No. 7,494,771, which is incorporated herein by reference in its entirety. As disclosed in International Publication No. WO 03 / 008636, such general cell lysis methods are effective for a wide variety of target organisms and sample matrices. Other, less general-purpose lysis methods also exist that are specifically designed or utilize specific enzymatic or chemical activity to target a particular species or group of organisms. For example, ACP enzymes are commonly used to lyse Gram-positive bacteria (Ezaki et al., J. Clin. Microbiol., 16(5):844-846 (1982); Paule et al., J. Mol. Diagn., 6(3):191-196 (2004); U.S. Pat. No. 3,649,454; all incorporated herein by reference in their entireties) and mycobacteria (U.S. Pat. No. 5,185,242, incorporated herein by reference in their entireties), but are generally considered to be less effective at lysing Gram-negative species such as Escherichia coli and Pseudomonas aeruginosa (U.S. Pat. No. 3,649,454, incorporated herein by reference in their entireties).

[0081] Nucleic acid testing The methods described herein may include, for example, nucleic acid testing. For example, testing may include testing for a target nucleic acid sequence in a sample. Various forms of nucleic acid testing may be used in the embodiments disclosed herein, including, but not limited to, tests involving nucleic acid amplification. The target nucleic acid (e.g., gDNA, mRNA) may be single-stranded or double-stranded. The source of the target nucleic acid may be any source (e.g., any sample). In some embodiments, the target nucleic acid is bacterial nucleic acid (e.g., bacterial genomic DNA (gDNA) or mRNA). Thus, the compositions and methods provided herein may be utilized to detect the presence of bacterial nucleic acid within a population of nucleic acids (e.g., in a sample).

[0082] Provided herein are compositions and methods for detecting a target nucleic acid (e.g., the toxR gene of V. parahaemolyticus) in a sample, which can detect the target nucleic acid with high sensitivity. In some embodiments, the compositions and methods provided herein can be used to detect a target nucleic acid present in a sample containing multiple nucleic acids (including the target nucleic acid and multiple non-target nucleic acids), where the target nucleic acid is present in a sample containing more than 10 7 One or more copies (e.g., 10 6 One or more copies per species of non-target nucleic acid, 10 5 One or more copies per species of non-target nucleic acid, 10 4 One or more copies per species of non-target nucleic acid, 10 3 One or more copies per species of non-target nucleic acid, 10 2 In some embodiments, the disclosed methods may be used to detect a target nucleic acid present in a sample containing multiple nucleic acids (including a target nucleic acid and multiple non-target nucleic acids), where the target nucleic acid is present at 1 or more copies per 10 non-target nucleic acid, 1 or more copies per 50 non-target nucleic acids, 1 or more copies per 20 non-target nucleic acids, 1 or more copies per 10 non-target nucleic acids, or 1 or more copies per 5 non-target nucleic acids. 18 One or more copies (e.g., 10 15 One or more copies per species of non-target nucleic acid, 10 12 One or more copies per species of non-target nucleic acid, 10 9 One or more copies per species of non-target nucleic acid, 10 6 One or more copies per species of non-target nucleic acid, 10 5 One or more copies per species of non-target nucleic acid, 10 4 One or more copies per species of non-target nucleic acid, 10 3 One or more copies per species of non-target nucleic acid, 10 2one or more copies per species of non-target nucleic acid, one or more copies per 50 species of non-target nucleic acid, one or more copies per 20 species of non-target nucleic acid, one or more copies per 10 species of non-target nucleic acid, or one or more copies per 5 species of non-target nucleic acid).

[0083] In some embodiments, the detection threshold for methods of detecting a disclosed target nucleic acid (e.g., the toxR gene of V. parahaemolyticus) in a sample is 10 nM or less. As used herein, the term "detection threshold" may describe the minimum amount of target nucleic acid that must be present in a sample for detection to occur. Thus, as an illustrative example, if the detection threshold is 10 nM, a signal can be detected when the target nucleic acid is present in a sample at a concentration of 10 nM or greater. In some embodiments, the detection threshold (for detecting a target nucleic acid in the disclosed methods) is in the range of 500 fM to 1 nM (e.g., 500 fM to 500 pM, 500 fM to 200 pM, 500 fM to 100 pM, 500 fM to 10 pM, 500 fM to 1 pM, 800 fM to 1 nM, 800 fM to 500 pM, 800 fM to 200 pM, 800 fM to 100 pM, 800 fM to 1 pM, 1 pM to 1 nM, 1 pM to 500 pM, 1 pM to 200 pM, 1 pM to 100 pM, or 1 pM to 10 pM, or a number or range between any two of these values) (where concentration refers to the threshold concentration of the target nucleic acid at which the target nucleic acid can be detected). In some embodiments, the disclosed methods have a detection threshold in the range of 800 fM to 100 pM. In some embodiments, the disclosed methods have a detection threshold in the range of 1 pM to 10 pM. In some embodiments, the disclosed methods have a detection threshold in the range of 10 fM to 500 fM, e.g., 10 fM to 50 fM, 50 fM to 100 fM, 100 fM to 250 fM, or 250 fM to 500 fM, or a number or range between any two of these values.

[0084] In some embodiments, the minimum concentration of a target nucleic acid (e.g., the toxR gene of V. parahaemolyticus) that can be detected in a sample is in the range of 500 fM to 1 nM (e.g., 500 fM to 500 pM, 500 fM to 200 pM, 500 fM to 100 pM, 500 fM to 10 pM, 500 fM to 1 pM, 800 fM to 1 nM, 800 fM to 500 pM, 800 fM to 200 pM, 800 fM to 100 pM, 800 fM to 10 pM, 800 fM to 1 pM, 1 pM to 1 nM, 1 pM to 500 pM, 1 pM to 200 pM, 1 pM to 100 pM, or 1 pM to 10 pM, or a number or range between any two of these values). In some embodiments, the minimum concentration at which the target nucleic acid can be detected in a sample ranges from 800 fM to 100 pM, hi some embodiments, the minimum concentration at which the target nucleic acid can be detected in a sample ranges from 1 pM to 10 pM.

[0085] In some embodiments, the detection threshold (for detecting a target nucleic acid in the disclosed methods) is between 1 aM and 1 nM (e.g., between 1 aM and 500 pM, between 1 aM and 200 pM, between 1 aM and 100 pM, between 1 aM and 10 pM, between 1 aM and 1 pM, between 100 aM and 1 nM, between 100 aM and 500 pM, between 100 aM and 200 pM, between 100 aM and 100 pM, between 100 aM and 10 pM, between 100 aM and 1 pM). , 250aM~1nM, 250aM~500pM, 250aM~200pM, 250aM~100pM, 250aM~10pM, 250aM~1pM, 500aM~1nM, 500aM ~500pM, 500aM~200pM, 500aM~100pM, 500aM~10pM, 500aM~1pM, 750aM~1nM, 750aM~500pM, 750aM~200p M, 750aM~100pM, 750aM~10pM, 750aM~1pM, 1fM~1nM, 1fM~500pM, 1fM~200pM, 1fM~100pM, 1fM~10pM, 1 fM~1pM, 500fM~500pM, 500fM~200pM, 500fM~100pM, 500fM~10pM, 500fM~1pM, 800fM~1nM, 800fM~500p The detection threshold may be in the range of 1 aM to 800 aM. In some embodiments, the disclosed methods have a detection threshold in the range of 50 aM to 1 pM. In some embodiments, the disclosed methods have a detection threshold in the range of 50 aM to 500 fM.

[0086] In some embodiments, the minimum concentration at which a target nucleic acid (e.g., the toxR gene of V. parahaemolyticus) can be detected in a sample is between 1 aM and 1 nM (e.g., between 1 aM and 500 pM, between 1 aM and 200 pM, between 1 aM and 100 pM, between 1 aM and 1 pM, between 100 aM and 1 nM, between 100 aM and 500 pM, between 100 aM and 200 pM, between 100 aM and 100 pM, 100aM~10pM, 100aM~1pM, 250aM~1nM, 250aM~500pM, 250aM~200pM, 250aM~100pM, 250aM~10pM, 250 aM~1pM, 500aM~1nM, 500aM~500pM, 500aM~200pM, 500aM~100pM, 500aM~10pM, 500aM~1pM, 750aM~1 nM, 750aM~500pM, 750aM~200pM, 750aM~100pM, 750aM~10pM, 750aM~1pM, 1fM~1nM, 1fM~500pM, 1fM ~200pM, 1fM~100pM, 1fM~10pM, 1fM~1pM, 500fM~500pM, 500fM~200pM, 500fM~100pM, 500fM~10pM, The minimum concentration at which a target nucleic acid can be detected in a sample is in the range of 500 fM to 1 pM, 800 fM to 1 nM, 800 fM to 500 pM, 800 fM to 200 pM, 800 fM to 100 pM, 800 fM to 10 pM, 800 fM to 1 pM, 1 pM to 1 nM, 1 pM to 500 pM, 1 pM to 200 pM, 1 pM to 100 pM, or 1 pM to 10 pM, or a number or range between any two of these values). In some embodiments, the minimum concentration at which a target nucleic acid can be detected in a sample is in the range of 1 aM to 500 pM. In some embodiments, the minimum concentration at which a target nucleic acid can be detected in a sample is in the range of 100 aM to 500 pM. In some embodiments, the compositions or methods provided herein exhibit attomolar (aM) detection sensitivity. In some embodiments, the subject compositions or methods exhibit femtomolar (fM) detection sensitivity. In some embodiments, the subject compositions or methods exhibit picomolar (pM) detection sensitivity, hi some embodiments, the subject compositions or methods exhibit nanomolar (nM) detection sensitivity.

[0087] As used herein, nucleic acid amplification may refer to any known procedure for obtaining multiple copies of a target nucleic acid sequence or its complement or fragments thereof using sequence-specific methods. Examples of known amplification methods include, but are not limited to, polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA) (e.g., multiple displacement amplification (MDA)), replicase-mediated amplification, immuno-amplification, nucleic acid sequence-based amplification (NASBA), self-sustained sequence replication (3SR), rolling circle amplification, and transcription-mediated amplification (TMA).See, e.g., Mullis, "Process for Amplifying, Detecting, and / or Cloning Nucleic Acid Sequences," U.S. Pat. No. 4,683,195; Walker, "Strand Displacement Amplification," U.S. Pat. No. 5,455,166; Dean et al., "Multiple Displacement Amplification," U.S. Pat. No. 6,977,148; Notomi et al., "Process for Synthesizing Nucleic Acids," U.S. Pat. No. 6,410,278; Landegren et al., U.S. Pat. No. 4,988,617, "Method of detecting a nucleotide change in nucleic acids;" Birkenmeyer, "Amplification of Target Nucleic Acids Using Gap Filling Ligase Chain Reaction," U.S. Pat. No. 5,427,930; Cashman, "Blocked-Polymerase Polynucleotide Immunoassay Method and Kit," U.S. Pat. No. 5,849,478; Kacian et al., "Nucleic Acid Sequence Amplification," U.S. Pat. No. 5,849,478. See, for example, U.S. Patent No. 5,399,491; Malek et al., "Enhanced Nucleic Acid Amplification Process," U.S. Patent No. 5,130,238; Lizardi et al., BioTechnology, 6:1197 (1988); Lizardi et al., U.S. Patent No. 5,854,033, "Rolling circle replication reporter systems." In some embodiments, two or more of the foregoing nucleic acid amplification methods can be performed, for example, sequentially.

[0088] For example, LCR amplification uses at least four distinct oligonucleotides to amplify a target and its complementary strand through multiple cycles of hybridization, ligation, and denaturation (European Patent No. 0320308). SDA amplifies by using primers containing recognition sites for restriction endonucleases to nick one strand of a hemi-modified DNA duplex containing the target sequence, followed by amplification in a series of primer extension and strand displacement steps (Walker et al., U.S. Patent No. 5,422,252).

[0089] PCR is a method well known in the art for amplifying nucleic acids. PCR involves the amplification of a target sequence using two or more extendible sequence-specific oligonucleotide primers that flank the target sequence. A nucleic acid containing the target sequence of interest is subjected to multiple rounds of thermal cycling (denaturation, annealing, and extension) in the presence of primers, a thermostable DNA polymerase (e.g., Taq polymerase), and various dNTPs, resulting in amplification of the target sequence. PCR uses multiple rounds of primer extension reactions in which complementary strands of defined regions of a DNA molecule are simultaneously synthesized by the thermostable DNA polymerase. At the end of each cycle, each newly synthesized DNA molecule serves as a template for the next cycle. During these repeated reaction rounds, the number of newly synthesized DNA strands increases exponentially, as the initial template DNA is replicated thousands or millions of times after 20 to 30 reaction cycles. Methods for performing different types and formats of PCR have been described exhaustively in the literature, e.g., by Mullis et al. in "PCR Primer: A Laboratory Manual" Dieffenbach and Dveksler, eds. Cold Spring Harbor Laboratory Press, 1995, in patents (e.g., U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,800,159), and in academic publications (e.g., Mullis et al. 1987, Methods in Enzymology, 155:335-350), the contents of each reference being incorporated herein by reference in their entirety.

[0090] PCR can result in double-stranded amplification products suitable for post-amplification processing. If desired, amplification products can be detected by visualization with agarose gel electrophoresis, by enzyme immunoassay formats using probe-based colorimetric detection, by fluorescence techniques, or by other detection means known to those of skill in the art.

[0091] A wide variety of PCR methods are described in many sources, for example, Ausubel et al. (eds.), Current Protocols in Molecular Biology, Section 15, John Wiley & Sons, Inc., New York (1994). Examples of PCR methods include, but are not limited to, real-time PCR, end-point PCR, amplified fragment length polymorphism PCR (AFLP-PCR), Alu-PCR, asymmetric PCR, colony PCR, DD-PCR, denaturing PCR, hot-start PCR, in situ PCR, inverse PCR, long PCR, multiplex PCR, nested PCR, PCR-ELISA, PCR-RFLP, PCR-single strand conformation polymorphism (PCR-SSCP), quantitative competitive PCR (QC-PCR), rapid amplification of cDNA ends-PCR (RACE-PCR), random amplification of polymorphic DNA-PCR (RAPD-PCR), real-time PCR, repetitive extragenic palindromic-PCR (Rep-PCR), reverse transcriptase PCR (RT-PCR), TAIL-PCR, touchdown PCR, and vectorette PCR.

[0092] Real-time PCR, also called quantitative real-time polymerase chain reaction (QRT-PCR), can be used to simultaneously quantify and amplify specific portions of a given nucleic acid molecule. PCR can be used to determine whether a specific sequence is present in a sample; if so, to determine the number of copies of the sequence present. The term "real-time" can refer to periodic monitoring during PCR. Certain systems, such as the ABI 7700 Sequence Detection System and the ABI 7900HT Sequence Detection System (Applied Biosystems, Foster City, Calif.), perform monitoring at predetermined or user-defined time points during each thermal cycle. Real-time analysis by PCR with fluorescence resonance energy transfer (FRET) probes measures the change in fluorescent dye signal between cycles, preferably minus any internal control signal. Real-time procedures follow the general pattern of PCR, but nucleic acids are quantified after each round of amplification. Two examples of quantification methods are the use of fluorescent dyes (e.g., SYBR Green) that intercalate into double-stranded DNA and modified DNA oligonucleotide probes that fluoresce upon hybridization with complementary DNA. Intercalating agents exhibit relatively low fluorescence when unbound and relatively high fluorescence upon binding to double-stranded nucleic acid. Thus, intercalating agents can be used to monitor the accumulation of double-stranded nucleic acid during nucleic acid amplification reactions. Examples of such non-specific dyes useful in embodiments disclosed herein include intercalating agents such as SYBR Green I (Molecular Probes), propidium iodide, and ethidium bromide.

[0093] Fecal samples are often infected with multiple organisms. The disclosed primers and probes are resistant to mixed fecal infections. Due to the specific target sequences, primers, and probes, the methods and compositions disclosed herein can be used to detect the presence / absence or level of one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin) in a sample with high sensitivity, specificity, and accuracy.

[0094] The primers disclosed herein provide an assay panel for detecting one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin), and can be paired with additional PCR systems that use uniform chemical reaction and thermal PCR profiles to improve overall assay sensitivity and robustness.

[0095] In some embodiments, multiplex PCR is performed to amplify, for example, by direct or indirect means, one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin), and detect their presence or absence, allowing for the identification of V. parahaemolyticus and the determination of its potential virulence using a single test. In multiplex PCR, the presence or absence of V. parahaemolyticus may be determined by amplifying the toxR gene and detecting its presence or absence; the presence or absence of V. parahaemolyticus encoding TRH (TDH-related hemolysin) may be determined by amplifying the trh gene and detecting its presence or absence; and the presence or absence of V. parahaemolyticus encoding TDH (thermostable direct hemolysin) may be determined by amplifying the tdh gene and detecting its presence or absence.

[0096] Thus, some embodiments for detecting and / or identifying V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin) in a sample include providing a test sample; and contacting the sample under standard nucleic acid amplification conditions and / or stringent hybridization conditions with oligonucleotide primers capable of specifically hybridizing to and amplifying (1) the toxR gene of V. parahaemolyticus, (2) the tdh gene of V. parahaemolyticus, and (3) the trh gene of V. parahaemolyticus, and oligonucleotide probes capable of specifically hybridizing to (1) the toxR gene of V. parahaemolyticus, (2) the tdh gene of V. parahaemolyticus, and (3) the trh gene of V. parahaemolyticus. As described herein, the sample may be contacted with all of the primers and probes at once, or may be contacted first with some of the primers and probes and then with the remainder of the primers and probes.

[0097] The oligonucleotide probes may be, for example, between about 10 and about 45 nucleotides in length and may include a detectable moiety (e.g., a signal moiety, a detectable label). In some embodiments, the contacting step is performed under conditions that allow specific hybridization of the primers to the corresponding target gene region if the target organism is present in the sample. The presence and / or amount of probes specifically bound to the corresponding target gene region (if present in the test sample) can be determined, with the bound probe indicating the presence of the corresponding target organism in the sample. In some embodiments, the amount of bound probe is used to determine the amount of the corresponding target organism in the sample.

[0098] The determining step can be accomplished after the contacting step using any method known to those skilled in the art, including, but not limited to, in situ hybridization. Detection of hybrid duplexes (i.e., by probes specifically bound to target gene regions) can be performed by a number of methods. Typically, hybridization duplexes are separated from unhybridized nucleic acids, and then labels attached to the duplexes are detected. Such labels refer to radioactive tags, fluorescent tags, biological tags, or enzymatic tags, as standardly used in the art. The label may be conjugated to an oligonucleotide probe or to nucleic acids derived from a biological sample. Those skilled in the art will understand that wash steps can be used to wash away excess sample / target nucleic acids or oligonucleotide probes (and unbound conjugates, if applicable). Furthermore, standard heterogeneous assay formats are suitable for detecting hybrids using labels present on the oligonucleotide primers and probes. Determining the presence or amount of one or more amplicons can include contacting the amplicons with a plurality of oligonucleotide probes, at least one of which comprises a fluorescent-emitting moiety and a fluorescent-quenching moiety. In some embodiments, determining the presence or amount of one or more amplicons includes measuring a detection signal, e.g., a detection signal from a probe.

[0099] In some embodiments, determining the presence or amount of one or more amplicons comprises measuring a detector signal, such as a detector signal from a probe (e.g., after cleavage of the probe by the 5'-3' exonuclease activity of a PCR polymerase (e.g., Taq)). Determining the presence or amount of one or more amplicons can comprise measuring a detector signal, such as a detector signal from a probe. In some embodiments, the measurement can be quantitative, e.g., in the sense that the amount of signal detected can be used to determine the amount of target nucleic acid (e.g., the toxR gene of V. parahaemolyticus) present in a sample. In some embodiments, the measurement can be qualitative, e.g., in the sense that the presence or absence of a detector signal can indicate the presence or absence of target DNA (e.g., a virus, a SNP, etc.). In some embodiments, a detector signal (e.g., above a given threshold level) will not be present unless target DNA (e.g., a virus, a SNP, etc.) is present above a certain threshold concentration. In some embodiments, the disclosed methods can be used to determine the amount of a target nucleic acid (e.g., the toxR gene of V. parahaemolyticus) in a sample (e.g., a sample containing a target nucleic acid and multiple non-target nucleic acids). Determining the amount of the target nucleic acid in a sample can include comparing the amount of a detection signal generated from a test sample with the amount of a detection signal generated from a reference sample. Determining the amount of the target nucleic acid in a sample can include measuring the detection signal to generate a test measurement; measuring the detection signal generated by the reference sample to generate a reference measurement; and comparing the test measurement to the reference measurement to determine the amount of the target nucleic acid present in the sample. Determining the amount of the target nucleic acid in a sample can be used to derive the presence and / or amount of an organism containing the target nucleic acid in the sample.

[0100] In some embodiments, the detected signal measured is provided by a fluorescent dye pair in the probe. For example, in some embodiments, the disclosed methods comprise contacting the amplicon with a probe comprising a fluorescence resonance energy transfer (FRET) pair or a quencher / fluorophore pair, or both. In some embodiments, the disclosed methods comprise contacting the amplicon with a probe comprising a FRET pair. In some embodiments, the disclosed methods comprise contacting the amplicon with a probe comprising a fluorophore / quencher pair. Fluorescent-emitting dye pairs include FRET pairs or quencher / fluorophore pairs. In both FRET and quencher / fluorophore pair embodiments, the emission spectrum of one of the dyes overlaps with a region of the absorption spectrum of the other dye in the pair. As used herein, the term "fluorescent-emitting dye pair" is a general term used to encompass both "fluorescence resonance energy transfer (FRET) pairs" and "quencher / fluorophore pairs," both of which are discussed in more detail below. The term "fluorescent-emitting dye pair" is used interchangeably with the phrase "FRET pair and / or quencher / fluorophore pair."

[0101] In some embodiments (e.g., when the probe comprises a FRET pair), the probe provides an amount of detectable signal before cleavage, and the amount of detectable signal measured is reduced when the probe is cleaved. In some embodiments, the probe provides a first detectable signal (e.g., from the FRET pair) before cleavage and a second detectable signal (e.g., from the quencher / fluorophore pair) when the probe is cleaved. Thus, in some embodiments, the probe comprises a FRET pair and a quencher / fluorophore pair.

[0102] In some embodiments, the probe comprises a FRET pair. FRET is a process in which non-radiative energy transfer occurs from an excited fluorophore to a nearby second chromophore. The range over which energy transfer can occur is limited to approximately 10 nanometers (100 angstroms), and the efficiency of transfer is extremely sensitive to the separation distance between the fluorophores. Thus, as used herein, the term "FRET" (also known as "fluorescence resonance energy transfer"; "Förster resonance energy transfer") may refer to a physical phenomenon involving a donor fluorophore and a matching acceptor fluorophore, further selected so that the emission spectrum of the donor overlaps with the excitation spectrum of the acceptor, and a portion of the energy is transferred from the donor to the acceptor via quantum coupling effects, such that excitation of the donor causes excitation of the acceptor and emission from the acceptor when the donor and acceptor are close to each other (typically 10 nm or less). Thus, the FRET signal is used as a proximity gauge for the donor and acceptor; a signal is generated only if they are in close proximity to one another. Herein, a FRET donor moiety (e.g., a donor fluorophore) and a FRET acceptor moiety (e.g., an acceptor fluorophore) are collectively referred to as a "FRET pair."

[0103] Herein, a donor-acceptor pair (a FRET donor moiety and a FRET acceptor moiety) is referred to as a "FRET pair" or a "signal FRET pair." Thus, in some embodiments, a probe comprises two signal partners (a signal pair) where one signal partner is a FRET donor moiety and the other signal partner is a FRET acceptor moiety. Thus, when the signal partners are in close proximity (e.g., on the same RNA molecule), a probe comprising such a FRET pair (a FRET donor moiety and a FRET acceptor moiety) will exhibit a detectable signal (a FRET signal), but when the partners are separated (e.g., after cleavage of the probe by the 5'-3' exonuclease activity of a PCR polymerase (e.g., Taq)), the signal will be reduced (or absent). FRET donor and FRET acceptor moieties (FRET pairs) are known to those of skill in the art, and any convenient FRET pair (eg, any convenient pair of donor and acceptor moieties) can be used.

[0104] In some embodiments, one signal partner of a signal-quenching pair provides a signal for detection and the other signal partner is a quenching moiety that quenches the signal for detection of the first signal partner (e.g., the quenching moiety quenches the signal of the signal moiety when the signal partners are in close proximity to each other, e.g., when the signal partners of a signal pair are in close proximity, the quenching moiety quenches the signal from the signal moiety such that the signal from the signal moiety is reduced (quenched)).

[0105] For example, in some embodiments, upon cleavage of the probe, the amount of signal for detection increases. For example, in some embodiments, the signal exhibited by one signal partner (signal moiety, fluorescent moiety) is quenched by the other signal partner (quencher signal moiety, fluorescent quenching moiety) when both are present on the same ssDNA molecule, e.g., prior to cleavage by the 5'-3' exonuclease activity of a PCR polymerase (e.g., Taq). Such signal pairs are referred to herein as "quencher / fluorophore pairs," "quencher pairs," or "signal-quenching pairs." For example, in some embodiments, one signal partner (e.g., a first signal partner) is a signal moiety that provides a signal for detection that is quenched by a second signal partner (e.g., a quencher moiety). Thus, the signal partners of such a quencher / fluorophore pair will provide a detectable signal when the partners are separated (e.g., after cleavage of the probe by the 5'-3' exonuclease activity of a PCR polymerase (e.g., Taq)), but the signal will be quenched when the partners are in close proximity (e.g., before cleavage of the probe by the 5'-3' exonuclease activity of a PCR polymerase (e.g., Taq)).

[0106] A quencher moiety may quench the signal from the signaling moiety (e.g., prior to cleavage of the probe by the 5'-3' exonuclease activity of a PCR polymerase (e.g., Taq)) to varying degrees. In some embodiments, a quencher moiety quenches the signal from the signaling moiety if the signal detected in the presence of the quencher moiety (when the signal partners are close to each other) is 95% or less of the signal detected in the absence of the quencher moiety (when the signal partners are spaced apart). For example, in some embodiments, the signal detected in the presence of the quencher moiety may be 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 15% or less, 10% or less, or 5% or less of the signal detected in the absence of the quencher moiety. In some embodiments, in the presence of the quenching moiety, no signal (eg, a signal above background) is detected.

[0107] In some embodiments, the signal detected in the absence of the quenching moiety (when the signal partners are spaced apart) is at least 1.2 times greater (e.g., at least 1.3 times, at least 1.5 times, at least 1.7 times, at least 2 times, at least 2.5 times, at least 3 times, at least 3.5 times, at least 4 times, at least 5 times, at least 7 times, at least 10 times, at least 20 times, or at least 50 times greater, or any number or range between any two of these values) than the signal detected in the presence of the quenching moiety (when the signal partners are close to each other).

[0108] In some embodiments, the signal moiety is a fluorescent label. In some such embodiments, the quenching moiety quenches the signal (e.g., light signal) from the fluorescent label (e.g., by absorbing energy within the emission spectrum of the label). Thus, when the quenching moiety is not in close proximity to the signal moiety, the signal is not absorbed by the quenching moiety and the emission (signal) from the fluorescent label is detectable. Any convenient donor / acceptor pair (signal moiety / quenching moiety pair) can be used, and many suitable pairs are known in the art. In some embodiments, the quencher moiety absorbs energy from the signal moiety (also referred to herein as a "detectable label" or "detection moiety") and then emits a signal (e.g., light of a different wavelength). Thus, in some embodiments, the quencher moiety is itself a signal moiety (e.g., the signal moiety can be 6-carboxyfluorescein while the quencher moiety can be 6-carboxy-tetramethylrhodamine), and in some such embodiments, the pair could also be a FRET pair. In some embodiments, the quencher moiety is a dark quencher. A dark quencher can absorb excitation energy and dissipate the energy in a different form (e.g., as heat). Thus, a dark quencher, by itself, results in minimal to zero fluorescence (does not fluoresce).

[0109] In some embodiments, probe cleavage can be detected by measuring a colorimetric readout. For example, release of a fluorophore (e.g., release from a FRET pair, release from a quencher / fluorophore pair, etc.) can result in a wavelength shift (and thus a color shift) of the detection signal. Thus, in some embodiments, probe cleavage can be detected by a color shift. Such a shift can be manifested as a loss of signal of one color (wavelength), a gain of signal of another color, a change in the distribution of one color to another, etc.

[0110] Disclosed herein are methods and compositions for multiplex real-time PCR capable of simultaneously detecting four gene targets: V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin), all in a single reaction. In some embodiments, a method for detecting V. parahaemolyticus in a sample is provided.In some embodiments, the method includes contacting the sample with a plurality of primer pairs, wherein the plurality of primer pairs are capable of hybridizing to a toxR gene of V. parahaemolyticus, at least one primer pair, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 1-8, or a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences set forth in SEQ ID NOs: 1-8; at least one primer pair capable of hybridizing to the V. parahaemolysin (tdh) gene, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 14 to 23, or a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences set forth in SEQ ID NOs: 14 to 23; and The method includes a step of including at least one primer pair capable of hybridizing to the hemolysin gene, wherein each primer in the at least one primer pair comprises any one of the sequences set forth in SEQ ID NOs: 29-38, or a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences set forth in SEQ ID NOs: 29-38.The method may include generating an amplicon of a toxR gene sequence, an amplicon of a trh gene sequence, an amplicon of a tdh gene sequence, or any combination thereof, when the sample contains one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding thermostable direct hemolysin (TDH). The method may include determining the presence or amount of one or more amplicons in the sample as an indication of the presence of one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding thermostable direct hemolysin (TDH). The method may include contacting the sample with at least one control primer pair capable of hybridizing to the yaiO gene of E. coli, wherein each primer in the at least one control primer pair comprises any one of the sequences set forth in SEQ ID NOs: 44-53, or a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to any one of the sequences set forth in SEQ ID NOs: 44-53; and, if the sample contains E. coli, generating an amplicon of the E. coli yaiO gene sequence from the sample; and determining the presence or amount of the amplicon of the E. coli yaiO gene sequence in the sample as an indication of the presence of E. coli. In some embodiments, the sample is contacted with a composition comprising a plurality of primer pairs and at least one control primer pair capable of hybridizing to the yaiO gene of E. coli.

[0111] The sample may be a biological sample or an environmental sample. An environmental sample may be obtained from a food sample, a beverage sample, a paper surface, a fabric surface, a metal surface, a wood surface, a plastic surface, a soil sample, a freshwater sample, a wastewater sample, a saltwater sample, exposure to air or other gas samples, cultures thereof, or any combination thereof. A biological sample may be obtained from a tissue sample, saliva, blood, plasma, serum, feces, urine, sputum, mucus, lymph, synovial fluid, cerebrospinal fluid, ascites, pleural effusion, seroma, pus, a skin swab or mucosal surface, cultures thereof, or any combination thereof. In some embodiments, the biological sample comprises or is derived from a fecal sample.

[0112] In some embodiments, the plurality of primer pairs comprises a first primer comprising the sequence of SEQ ID NO: 1, 3, 5, or 7, a second primer comprising the sequence of SEQ ID NO: 2, 4, 6, or 8, a third primer comprising the sequence of SEQ ID NO: 14, 16, 18, 20, or 22, a fourth primer comprising the sequence of SEQ ID NO: 15, 17, 19, 21, or 23, a fifth primer comprising the sequence of SEQ ID NO: 29, 31, 33, 35, or 37, and a sixth primer comprising the sequence of SEQ ID NO: 30, 32, 34, 36, or 38. In some embodiments, the plurality of primer pairs comprises a seventh primer comprising the sequence of SEQ ID NO: 44, 46, 48, 50, or 52, and an eighth primer comprising the sequence of SEQ ID NO: 45, 47, 49, 51, or 53.

[0113] In some embodiments, the primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus is SEQ ID NO: 1 and 2, SEQ ID NO: 3 and 4, SEQ ID NO: 5 and 6, or SEQ ID NO: 7 and 8; the primer pair capable of hybridizing to the trh gene of V. parahaemolyticus is SEQ ID NO: 14 and 15, SEQ ID NO: 16 and 17, SEQ ID NO: 18 and 19, SEQ ID NO: 20 and 21, or SEQ ID NO: 22 and 23; and the primer pair capable of hybridizing to the tdh gene of V. parahaemolyticus is SEQ ID NO: 29 and 30, SEQ ID NO: 31 and 32, SEQ ID NO: 33 and 34, SEQ ID NO: 35 and 36, or SEQ ID NO: 37 and 38. In some embodiments, the control primer pair capable of hybridizing to the yaiO gene of E. coli is SEQ ID NO: 44 and 45, SEQ ID NO: 46 and 47, SEQ ID NO: 48 and 49, SEQ ID NO: 50 and 51, or SEQ ID NO: 52 and 53.

[0114] In some embodiments, the amplification is carried out using a method selected from the group consisting of polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), replicase-mediated amplification, immunoamplification, nucleic acid sequence-based amplification (NASBA), self-sustained sequence replication (3SR), rolling circle amplification, and transcription-mediated amplification (TMA). The PCR may be real-time PCR. The PCR may be quantitative real-time PCR (QRT-PCR). Each primer may comprise an exogenous nucleotide sequence.

[0115] In some embodiments, determining the presence or amount of one or more amplicons comprises contacting the amplicon with a plurality of oligonucleotide probes, wherein each of the plurality of oligonucleotide probes comprises a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, 54-58, or a sequence exhibiting at least about 85% identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) to a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, 54-58. Each of the plurality of oligonucleotide probes may comprise a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, 54-58. Each of the multiple oligonucleotide probes can consist of a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58. Each probe can be flanked by a complementary sequence at the 5' end and a complementary sequence at the 3' end. In some embodiments, one of the complementary sequences comprises a fluorescent moiety, and the other complementary sequence comprises a fluorescence quenching moiety. In some embodiments, at least one of the multiple oligonucleotide probes comprises a fluorescent moiety and a fluorescence quenching moiety. As described herein, amplification can be performed by real-time PCR, e.g., quantitative real-time PCR (QRT-PCR). Primers suitable for use in the methods and compositions described herein can contain exogenous nucleotide sequences that allow for post-amplification manipulation of the amplification product without significantly affecting the amplification itself. In some embodiments, primers and / or probes can be flanked by complementary sequences comprising a fluorophore at the 5' end and a fluorescence quencher at the 3' end. Any of the oligonucleotide probes disclosed herein can include a fluorescence-emitting moiety, a fluorescence-quenching moiety, or both.

[0116] Disclosed herein are methods that are amenable to automation, thereby providing a high-throughput option for detecting and / or quantifying one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin) in a sample. A variety of multiplex PCR platforms, such as the BD MAX™ platform, Viper™ platform, or Viper™ LT platform, can be used to perform one or more steps of the disclosed methods. The methods can be performed in a multiplexed format. For example, nucleic acid amplification and / or detection, in some embodiments, involves performing multiplex PCR. [Example]

[0117] The following examples are presented to demonstrate particular situations and settings in which the present technology may be applied, and are not intended to limit the scope of the invention and claims contained in this disclosure.

[0118] Example 1 Multiplex detection of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin) The studies described in this example demonstrate the implementation of the compositions and methods presented herein on a BD MAX fully automated system. The compositions and methods disclosed herein can also be performed on other real-time PCR instruments, such as, for example, the ABI 7500.

[0119] Materials and Methods A total of 57 bacterial strains were used to validate the multiplex PCR and are presented in Table 4. These isolates included V. parahaemolyticus (n = 19), V. cholerae (n = 16), V. fluvialis (n = 1), V. alginolyticus (n = 1), V. mimicus (n = 1), V. vulnificus (n = 1), Aeromonas hydrophila (n = 1), Plesiomonas shigelloides (n = 1), diarrheagenic Escherichia coli (n = 8), Salmonella species (n = 6), and Shigella species (n = 2). The control strains used in this study were V. parahaemolyticus VP8 strains: TDH and TRH. All of these strains were provided by the China National CDC.

[0120] [Table 4]

[0121] This study utilized the BD MAX™ ExK™ TNA-2 Extraction Kit and 5X qPCR Mastermix. The genes targeted for the V. parahaemolyticus multiplex detection assay were the species-specific gene toxR, the gene encoding thermostable direct hemolysin (TDH), tdh, and the gene encoding TDH-related hemolysin (TRH), with the Escherichia coli yaiO gene selected as an internal control. These gene sequences were based on an alignment of available sequences deposited in the NCBI nr database (https: / / www.ncbi.nlm.nih.gov / nucleotide / ). All primers and probes were designed using Beacon Designer V8.20 and synthesized by Sangon Biotech (Shanghai, China). NCBI BLASTn was used to computerize specificity and sensitivity. To extract DNA from fecal samples, spiked and clinical samples were vortexed and 50 μl aliquots of each sample were added to BD MAX sample buffer tubes. Automated DNA extraction on a BD MAX using the BD MAX ExK TNA-2 extraction kit was performed according to the kit instructions.

[0122] For multiplex PCR reactions, 12.5 ul of PCR reaction mixture was prepared in each conical tube containing the primer / probe combinations disclosed herein at the working concentrations indicated in Table 5. Sample processing controls (SPCs) may include the yaiO gene of E. coli. [Table 5]

[0123] The conical tube containing 12.5 μl of the mixture was snapped onto a BD MAX TNA extraction strip. The final PCR reaction mixture was prepared by the BD MAX automatically adding and mixing 12.5 μl of purified DNA, prepared as described above, to the conical tube. The PCR thermal cycling profile was as follows: denaturation at 95°C for 5 minutes; and 40 cycles of denaturation at 95°C for 15 seconds, annealing and extension at 60°C for 43 seconds.

[0124] Amplification efficiency test As shown in Table 6, the primer / probe combinations presented herein, when used in the multiplex PCR method disclosed herein, resulted in excellent amplification efficiencies for toxR, trh, and tdh in fecal samples spiked with Vp8 strains. [Table 6]

[0125] Analysis sensitivity test To estimate the detection limit of the optimized multiplex PCR, 10 μl of a culture suspension of V. parahaemolyticus strain Vp8 was spiked with 50 μl of negative fecal specimen and vortexed before extraction. These were tested at six different bacterial concentrations, starting from the 2.5 McFarland standard, in three independent runs, with five replicates per run. Colony counts were performed using standard plate counting procedures. The highest 10-fold dilution at which a threshold cycle C value was observed was further diluted in three two-fold dilution series (1:2, 1:4, and 1:8) to find the lowest concentration at which a C value was detected. The lowest concentration yielding a C value was tested in 12 replicates to determine the limit of detection (LoD) of the assay, as presented in Table 7. Robust analytical sensitivity was observed for each target using the primer / probe combinations presented herein. [Table 7]

[0126] Analysis specificity test Analytical specificity was determined with test DNA extracted from a panel of positive and negative control isolates (Table 4). This panel consisted of 63 control isolates that represented a wide range of pathogenic isolates closely related to the target species or commonly found in fecal samples from diarrheal patients and identified using culture methods (Table 4). The assay accurately detected all of the V. parahaemolyticus isolates and showed no cross-reactivity with non-target isolates shown in Table 4 (Tables 8 and 9). Robust analytical specificity was observed for each target using the primer / probe combinations presented herein. [Table 8]

[0127] [Table 9]

[0128] Terminology In at least some of the previously described embodiments, one or more elements used in an embodiment may be used interchangeably in another embodiment, unless such substitution is technically impractical. Those skilled in the art will appreciate that various other omissions, additions, and modifications may be made to the methods and structures described above without departing from the scope of the claimed subject matter. All such modifications and variations are intended to fall within the scope of the subject matter defined by the appended claims.

[0129] With respect to the use of substantially any plural and / or singular terms herein, those skilled in the art can convert from the plural to the singular and / or vice versa, as appropriate to the context and / or application. Various singular / plural permutations may be specified herein for clarity. As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context dictates otherwise. Unless otherwise stated, any reference herein to "or" is intended to include "and / or."

[0130] Those skilled in the art will understand that the terms used generally herein, and in particular in the appended claims (e.g., the body of the appended claims), are generally intended as "open" terms (e.g., the term "including" shall be interpreted as "including, but not limited to," the term "having" shall be interpreted as "having at least," the term "including" shall be interpreted as "including, but not limited to," etc.). Those skilled in the art will further understand that where specific numbered claim recitations are intended, such intent will be expressly stated in the claims, and that, in the absence of such recitations, no such intent exists. For example, as an aid to understanding, the following appended claims may contain the use of the introductory phrases "at least one" and "one or more" to introduce claim recitations. However, the use of such phrases should not be deemed to imply that the introduction of a claim statement by the indefinite article "a" or "an" limits any particular claim containing such a claim statement introduction to embodiments containing only one such statement, even if the same claim includes the introductory phrase "one or more" or "at least one" and an indefinite article such as "a" or "an" (e.g., "a" and / or "an" shall be interpreted to mean "at least one" or "one or more"); the same applies to the use of definite articles used to introduce claim statements. Additionally, even when a specific number of claims is explicitly recited, those skilled in the art will recognize that such a statement should still be interpreted to mean at least the recited number (e.g., a statement of "two statements" alone, without other modifiers, means at least two statements, or two or more claim statements).Furthermore, when usage similar to "such as at least one of A, B, and C" is used, generally such a construction is intended in the sense that one of ordinary skill in the art would understand the usage (e.g., "a system having at least one of A, B, and C" would include, but is not limited to, a system having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). When usage similar to "such as at least one of A, B, or C" is used, generally such a construction is intended in the sense that one of ordinary skill in the art would understand the usage (e.g., "a system having at least one of A, B, or C" would include, but is not limited to, a system having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). It will be further understood by those skilled in the art that virtually any disjunctive and / or disjunctive phrase, whether in the description, claims, or drawings, presenting two or more alternative terms, should be understood to contemplate the possibility of including one of the terms, either of the terms, or both of the terms. For example, the phrase "A or B" will be understood to include the possibilities of "A" or "B" or "A and B."

[0131] Additionally, where features or aspects of the present disclosure are described in terms of a Markush group, one of skill in the art will recognize that the present disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group. As will be understood by those skilled in the art, for any and all purposes, e.g., with respect to providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of these subranges. Any ranges recited fully describe the same range and can be readily recognized as being divisible into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily divided into a lower third, middle third, upper third, etc. As will also be understood by those skilled in the art, all expressions such as "less than or equal to," "at least," "greater than," "less than," etc., refer to ranges that are inclusive of the recited numbers and can then be divided into the subranges discussed above. Finally, as will be understood by those skilled in the art, a range includes each individual member. Thus, for example, a group having 1 to 3 items refers to a group having 1, 2, or 3 items. Similarly, a group having 1 to 5 items refers to groups having 1, 2, 3, 4, or 5 items, and so on.

[0132] While various aspects and embodiments are disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. Various aspects and embodiments are disclosed herein for purposes of illustration and not limitation, the true scope and spirit being indicated by the following claims.

Claims

1. 1. A method for detecting V. parahaemolyticus in a sample, comprising: Contacting the sample with a plurality of primer pairs, the plurality of primer pairs comprising: at least one primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 1-8, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 1-8; At least one primer pair capable of hybridizing to the trh (TDH-related hemolysin) gene of V. parahaemolyticus, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 14-23, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 14-23; and At least one primer pair capable of hybridizing to the tdh (thermostable direct hemolysin) gene of V. parahaemolyticus, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 29-38, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 29-38. a step comprising: If the sample contains one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin), generating an amplicon of a toxR gene sequence, an amplicon of a trh gene sequence, an amplicon of a tdh gene sequence, or any combination thereof; and Determining the presence or amount of one or more amplicons as an indication of the presence of one or more of V. parahaemolyticus, V. parahaemolyticus encoding TRH (TDH-related hemolysin), and V. parahaemolyticus encoding TDH (thermostable direct hemolysin) in the sample. The method includes:

2. Contacting the sample with at least one control primer pair capable of hybridizing to the yaiO gene of E. coli, wherein each primer of the at least one control primer pair comprises any one of the sequences of SEQ ID NOs: 44-53, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 44-53; and if the sample contains E. coli, generating an amplicon of the yaiO gene sequence of E. coli from the sample; and determining the presence or amount of an amplicon of the yaiO gene sequence of E. coli as an indication of the presence of E. coli in the sample. The method of claim 1 further comprising:

3. 3. The method of claim 2, wherein the sample is contacted with a composition comprising a plurality of primer pairs and at least one control primer pair capable of hybridizing to the yaiO gene of E. coli.

4. The sample is a biological sample or an environmental sample, and optionally (i) the environmental sample may be obtained from a food sample, a beverage sample, a paper surface, a fabric surface, a metal surface, a wood surface, a plastic surface, a soil sample, a fresh water sample, a waste water sample, a salt water sample, exposure to air or other gas samples, cultures thereof, or any combination thereof; (ii) the biological sample may be obtained from a tissue sample, saliva, blood, plasma, serum, faeces, urine, sputum, mucus, lymph, synovial fluid, cerebrospinal fluid, ascites, pleural fluid, seroma, pus, a swab of skin or a mucosal surface, a culture thereof, or any combination thereof; and / or (iii) the biological sample may comprise or be derived from a fecal sample; The method according to any one of claims 1 to 3.

5. the plurality of primer pairs comprises a first primer comprising a sequence of SEQ ID NO: 1, 3, 5, or 7; a second primer comprising a sequence of SEQ ID NO: 2, 4, 6, or 8; a third primer comprising a sequence of SEQ ID NO: 14, 16, 18, 20, or 22; a fourth primer comprising a sequence of SEQ ID NO: 15, 17, 19, 21, or 23; a fifth primer comprising a sequence of SEQ ID NO: 29, 31, 33, 35, or 37; and a sixth primer comprising a sequence of SEQ ID NO: 30, 32, 34, 36, or 38; and / or The multiple primer pairs include a seventh primer having a sequence of SEQ ID NO: 44, 46, 48, 50, or 52, and an eighth primer having a sequence of SEQ ID NO: 45, 47, 49, 51, or 53; The method according to any one of claims 1 to 4.

6. Primer pairs capable of hybridizing to the toxR gene of V. parahaemolyticus are SEQ ID NOs: 1 and 2, SEQ ID NOs: 3 and 4, SEQ ID NOs: 5 and 6, or SEQ ID NOs: 7 and 8; Primer pairs capable of hybridizing to the trh gene of V. parahaemolyticus are SEQ ID NOs: 14 and 15, SEQ ID NOs: 16 and 17, SEQ ID NOs: 18 and 19, SEQ ID NOs: 20 and 21, or SEQ ID NOs: 22 and 23; The primer pairs capable of hybridizing to the tdh gene of V. parahaemolyticus are SEQ ID NOs: 29 and 30, SEQ ID NOs: 31 and 32, SEQ ID NOs: 33 and 34, SEQ ID NOs: 35 and 36, or SEQ ID NOs: 37 and 38; The method according to any one of claims 1 to 5.

7. The method according to any one of claims 2 to 6, wherein the control primer pair capable of hybridizing to the yaiO gene of E. coli is SEQ ID NO:44 and 45, SEQ ID NO:46 and 47, SEQ ID NO:48 and 49, SEQ ID NO:50 and 51, or SEQ ID NO:52 and 53. (i) the amplification is carried out using a method selected from the group consisting of polymerase chain reaction (PCR), ligase chain reaction (LCR), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), replicase-mediated amplification, immunoamplification, nucleic acid sequence-based amplification (NASBA), self-sustained sequence replication (3SR), rolling circle amplification, and transcription-mediated amplification (TMA), and optionally, the PCR may be real-time PCR or quantitative real-time PCR (QRT-PCR); and / or (ii) each primer comprises an exogenous nucleotide sequence; The method according to any one of claims 1 to 7.

9. 9. The method of any one of claims 1 to 8, wherein the step of determining the presence or amount of one or more amplicons comprises contacting the amplicons with a plurality of oligonucleotide probes, each of the plurality of oligonucleotide probes comprising a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58.

10. The method according to claim 9, wherein each of the plurality of oligonucleotide probes comprises a sequence selected from the group consisting of SEQ ID NOs: 9 to 13, 24 to 28, 39 to 43, and 54 to 58, or each of the plurality of oligonucleotide probes consists of a sequence selected from the group consisting of SEQ ID NOs: 9 to 13, 24 to 28, 39 to 43, and 54 to 58. (i) each probe is flanked by a complementary sequence at its 5' end and a complementary sequence at its 3' end, one complementary sequence optionally comprising a fluorescent moiety and the other complementary sequence comprising a fluorescent quenching moiety; or (ii) at least one of the plurality of oligonucleotide probes comprises a fluorescent emitting moiety and a fluorescent quenching moiety; The method according to any one of claims 9 to 10.

12. 1. A composition for detecting V. parahaemolyticus in a sample, comprising: at least one primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 1-8, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 1-8; At least one primer pair capable of hybridizing to the trh (TDH-related hemolysin) gene of V. parahaemolyticus, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 14-23, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 14-23; and At least one primer pair capable of hybridizing to the tdh (thermostable direct hemolysin) gene of V. parahaemolyticus, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 29-38, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 29-38. A composition comprising:

13. 13. The composition of claim 12, further comprising at least one control primer pair capable of hybridizing to the yaiO gene of E. coli, wherein each primer of the at least one control primer pair comprises any one of the sequences of SEQ ID NOs: 44-53, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 44-53.

14. At least one primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus comprises a primer comprising a sequence of SEQ ID NO: 1, 3, 5, or 7, and a primer comprising a sequence of SEQ ID NO: 2, 4, 6, or 8; At least one primer pair capable of hybridizing to the trh gene of V. parahaemolyticus comprises a primer comprising the sequence of SEQ ID NO: 14, 16, 18, 20, or 22, and a primer comprising the sequence of SEQ ID NO: 15, 17, 19, 21, or 23; At least one primer pair capable of hybridizing to the tdh gene of V. parahaemolyticus comprises a primer comprising the sequence of SEQ ID NO: 29, 31, 33, 35, or 37, and a primer comprising the sequence of SEQ ID NO: 30, 32, 34, 36, or 38; The composition according to any one of claims 12 to 13.

15. The composition according to any one of claims 13 to 14, wherein at least one control primer pair capable of hybridizing to the yaiO gene of E. coli comprises a primer comprising a sequence of SEQ ID NO: 44, 46, 48, 50, or 52, and a primer comprising a sequence of SEQ ID NO: 45, 47, 49, 51, or 53.

16. The composition of any one of claims 12 to 15, further comprising a plurality of oligonucleotide probes, each of the plurality of oligonucleotide probes comprising a sequence selected from the group consisting of SEQ ID NOs: 9 to 13, 24 to 28, 39 to 43, and 54 to 58, or a sequence exhibiting at least about 85% identity to a sequence selected from the group consisting of SEQ ID NOs: 9 to 13, 24 to 28, 39 to 43, and 54 to 58.

17. (i) each of the plurality of oligonucleotide probes comprises a sequence selected from the group consisting of SEQ ID NOs: 9 to 13, 24 to 28, 39 to 43, and 54 to 58, and optionally each of the plurality of oligonucleotide probes may consist of a sequence selected from the group consisting of SEQ ID NOs: 9 to 13, 24 to 28, 39 to 43, and 54 to 58; and / or (ii) at least one of the plurality of probes comprises a fluorescent moiety and a fluorescence quenching moiety; 17. The composition of claim 16.

18. A kit for detecting V. parahaemolyticus in a sample, comprising: at least one primer pair capable of hybridizing to the toxR gene of V. parahaemolyticus, wherein each primer of said at least one primer pair comprises any one of the sequences of SEQ ID NOs: 1-8, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 1-8; At least one primer pair capable of hybridizing to the trh (TDH-related hemolysin) gene of V. parahaemolyticus, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 14-23, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 14-23; At least one primer pair capable of hybridizing to the tdh (thermostable direct hemolysin) gene of V. parahaemolyticus, wherein each primer of the at least one primer pair comprises any one of the sequences of SEQ ID NOs: 29-38, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 29-38; and At least one control primer pair capable of hybridizing to the yaiO gene of E. coli, wherein each primer of the at least one control primer pair comprises any one of the sequences of SEQ ID NOs: 44-53, or a sequence exhibiting at least about 85% identity to any one of the sequences of SEQ ID NOs: 44-53; Kit including:

19. The method further comprises the steps of: providing a nucleic acid sequence comprising: a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58; and a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58; and optionally, (i) each of the plurality of oligonucleotide probes may consist of a sequence selected from the group consisting of SEQ ID NOs: 9-13, 24-28, 39-43, and 54-58; and / or (ii) at least one of the plurality of probes may comprise a fluorescent moiety and a fluorescent quenching moiety; The kit of claim 18.